

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/54, 9/12, A61K 31/70	A2	(11) International Publication Number: WO 00/52173 (43) International Publication Date: 8 September 2000 (08.09.00)
(21) International Application Number: PCT/CA00/00223 (22) International Filing Date: 2 March 2000 (02.03.00) (30) Priority Data: 60/122,516 2 March 1999 (02.03.99) US (71) Applicant (for all designated States except US): NPS ALLELIX CORP. [CA/CA]; 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): MUNROE, Donald [CA/CA]; 27 Wakefield Lane, Waterdown, Ontario L0R 2N3 (CA). GUPTA, Ashwani [CA/CA]; 7031 Dunrobin Way, Mississauga, Ontario L5N 6Y4 (CA). FALZONE, Germaine, R. [CA/CA]; 34 Brady Crescent, North York, Ontario M3L 2B5 (CA). (74) Agents: VAN ZANT, Joan, M. et al.; 77 Bloor Street West, Suite 1407, Toronto, Ontario M5S 1M2 (CA).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: CLONED HUMAN SPHINGOSINE KINASE HOMOLOGUES (57) Abstract The present invention provides newly identified and isolated polynucleotides and their polypeptides and their uses and in particular to newly identified and isolated polynucleotides and polypeptides of the sphingosine kinase family. Three isolated polynucleotides and polypeptides for three human SK homologues are described: SKA, SKB and SKC.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Cloned Human Sphingosine Kinase Homologues

Field of Invention

The present invention is related to the field of molecular biology. In particular
5 the present invention is related to newly identified and isolated polynucleotides and
their polypeptides and their uses and in particular to newly identified and isolated
polynucleotides and polypeptides of the sphingosine kinase family.

Background

10 Sphingolipids are complex structural lipids which are found in membranes.
One of the more prominent sphingolipids is sphingomyelin. Sphingomyelin is
hydrolyzed by sphingomyelinase to form ceramide which in turn is metabolized by
ceramidase to form sphingosine. Sphingosine kinase (SK) is the enzyme which
phosphorylates sphingosine to form sphingosine 1-phosphate (S1P) and thereby SK in
15 effect controls S1P production.

It has been suggested that S1P plays an intracellular role in cell proliferation
and inhibits and/or blocks apoptosis, among other things. S1P also acts as an
endogenous ligand for certain G-protein coupled receptors, including the edg-3
20 receptor. It has also been found that SK inhibitors block thrombin signalling
pathways and induce apoptosis.

Accordingly, in view of the role of SK and S1P in key pathways, it would be
desirable to have the cloned human SK homologues for use as drug targets. In
25 particular, using the human SK homologues, SK inhibitors could be determined
which inhibitors could be used in anti-proliferative diseases: cancer, psoriasis,
reactive gliosis; or to suppress inappropriate cell survival and to block inflammatory
S1P production in neurodegenerative diseases, demyelinating diseases, asthma, and
allergies

30

Summary of the Invention

The present invention provides the isolated polynucleotides and polypeptides for the human SK homologues. In particular, the present invention provides three
5 isolated polynucleotides and polypeptides for the three human SK homologues: SKA; SKB; and SKC; and variants thereof.

In accordance with an aspect of the present invention there is provided isolated polypeptides for the human SK homologues SKA, SKB and SKC comprising
10 the sequences as set out in Figures 3, 6 and 9, respectively, and variants thereof.

In accordance with another aspect of the present invention there is provided isolated polynucleotides of SKA, SKB and SKC comprising the sequences as illustrated in Figures 2, 5 and 8, respectively, and variants thereof.
15

In accordance with a further aspect of the present invention there are provided isolated polynucleotides encoding human SKA, SKB and SKC, including mRNAs, cDNAs, genomic DNAs. In addition, embodiments of the invention include diagnostic, prophylactic, clinical or therapeutical useful variants of these isolated
20 nucleotide sequences SKA, SKB and SKC and compositions thereof. Also included in an aspect of the invention are naturally occurring allelic variants of SKA, SKB and SKC and polypeptides encoded thereby.

In accordance with another aspect of the invention, there are provided
25 methods for producing the polypeptides for SKA, SKB and SKC and for determining inhibitors to such polypeptides, including antibodies.

In accordance with another aspect there are polynucleotides that hybridize to SKA, SKB and SKC nucleotide sequences, particularly under stringent conditions.
30

In accordance with yet another aspect of the invention, there are provided methods for identifying compounds which interact with the polypeptide or polynucleotide of SKA, SKB or SKC.

- 5 There are also provided compositions comprising a polypeptide or polynucleotide of SKA, SKB or SKC for administration to a cell or to a multicellular organism.

10 **Description of the Figures**

Figure 1 is an illustration of the full length nucleotide sequence of the cDNA of human SKA.

- 15 Figure 2 is an illustration of the nucleotide sequence of the coding region of SKA.

Figure 3 is an illustration of the predicted amino acid sequence of SKA as illustrated in Figure 2.

20

Figure 4 is an illustration of the full length nucleotide sequence of the cDNA of human SKB.

- 25 Figure 5 is an illustration of the nucleotide sequence of the coding region of SKB.

Figure 6 is an illustration of the predicted amino acid sequence of SKB as illustrated in Figure 5.

- 30 Figure 7 is an illustration of the full length nucleotide sequence of the cDNA of human SKC.

Figure 8 is an illustration of the nucleotide sequence of the coding region of SKC.

5 Figure 9 is an illustration of the predicted amino acid sequence of SKC as illustrated in Figure 8.

Figure 10 is an illustration of the alignment of the amino acid sequences of human SKA, SKB and SKC.

10

Figure 11 is an illustration of the results of the phosphorylation assays exemplified in Example 4 for SKA, SKB and SKB.

Detailed Description

15

Definitions

The following definitions are used herein for the purpose of describing particular terms used in the application. Any terms not specifically defined should be
20 given the meaning commonly understood by one of ordinary skill in the art to which the invention pertains.

“Biologically Active” refers to those forms, fragments, or domains of any sphingosine kinase polypeptide which retain at least some of the biological and/or
25 antigenic activities of a naturally occurring sphingosine kinase.

“Chimeric” molecules may be constructed by introducing all or part of the nucleotide sequence of this invention into a vector containing additional nucleic acid sequence which might be expected to change any one (or more than one) of the
30 following characteristics: cellular location, distribution, ligand-binding affinities, interchain affinities, degradation/turnover rate, signaling, etc.

“Derivative” refers to those amino acid sequences and nucleotide sequences which have been chemically modified. Such techniques for polypeptide derivatives include: ubiquitination; labeling (see above); pegylation (derivatization with polyethylene glycol); and chemical insertion or substitution of amino acids such as ornithine which do not normally occur in human proteins. A nucleotide sequence derivative would encode an amino acid which retains its essential biological activity and characteristics of the natural molecule.

10 As used herein “human sphingosine kinase” refers to the isolated polypeptide or polynucleotide sequences of the different isoforms of human sphingosine kinase, including human SKA, human SKB and human SKC, in either naturally occurring or synthetic form.

15 As used herein, “human sphingosine kinase A” or “human SKA” refers to the polynucleotide or polypeptide of an isoform of human sphingosine kinase as illustrated by the sequences of Figure 2 and 3, respectively, and by polypeptide sequences which preferably have at least 85% sequence identity with each other and Figure 3, and more preferably at least 90% sequence identity with each other and Figure 3, and most preferably at least 95% sequence identity with each other and Figure 3, or polynucleotide sequences which encode such polypeptide sequence identities.

25 As used herein, “human sphingosine kinase B” or “human SKB” refers to the polynucleotide or polypeptide of an isoform of human sphingosine kinase as illustrated by the sequences of Figure 5 and 6, respectively, and to the polypeptide sequences which preferably have at least 85% sequence identity with each other and Figure 6, and more preferably at least 90% sequence identity with each other and Figure 6, and most preferably at least 95% sequence identity with each other and Figure 6 or polynucleotide sequences which encode such polypeptide sequence identities.

30

As used herein, "human sphingosine kinase C" or "human SKC" refers to the polynucleotide or polypeptide of an isoform of human sphingosine kinase as illustrated by the sequences of Figure 8 and 9, respectively, and by the polypeptide sequences which preferably have at least 85% sequence identity with each other and
5 Figure 9, and more preferably at least 90% sequence identity with each other and Figure 9, and most preferably at least 95% sequence identity with each other and Figure 9 or polynucleotide sequences which encode such polypeptide sequence identities.

10 "Inhibitor" is any substance which retards or prevents a biochemical, cellular or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.

"Insertions" or "deletions" are typically in the range of about 1 to 5 amino
15 acids and do not result in a change in biological activity of the polypeptide. The variation allowed may be experimentally determined by producing the peptide synthetically or by systematically making insertions, deletions, or substitutions of nucleotides in the human sphingosine kinase sequence using recombinant DNA techniques.

20 As used herein "isolated" means separated from nucleotide sequences that encode other proteins or from other peptides. For example, a polypeptide or polynucleotide naturally present in a living organism is not "isolated" but when separated from the coexisting nucleotides/peptides it is "isolated".

25 "Nucleotide sequences" as used herein are oligonucleotides, polynucleotides, and fragments or portions thereof, and are DNA or RNA of genomic or synthetic origin which may be single or double stranded, and represent the sense or complement or antisense strands.

30 An "oligonucleotide" is a stretch of nucleotide residues, which has a

sufficient number of bases to be used as an oligomer, amplimer or probe in a polymerase chain reaction (PCR). Oligonucleotides are prepared from genomic or cDNA sequence and are used to amplify, reveal or confirm the presence of a similar DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise
5 portions of a DNA sequence having at least about 10 nucleotides and as many as about 35 nucleotides, preferably about 25 nucleotides.

An "oligopeptide" is a short stretch of amino acid residues and may be expressed from an oligonucleotide. It may be functionally equivalent to and the same
10 length as (or considerably shorter than) a "fragment", "portion", or "segment" of a polypeptide. Such sequences comprise a stretch of amino acid residues of at least about 5 amino acids and often about 17 or more amino acids, typically at least about 9 to 13 amino acids, and of sufficient length to display biological and/or antigenic activity.

15

As used herein "purified" refers to amino acid sequences that are removed from their natural environment, and are isolated or separated, and are at least 60% free, preferably at least 75 % free, and most preferably at least 90% free from other components with which they are naturally associated.

20

A "portion" or "fragment" of a nucleotide or nucleic acid sequence comprises all or any part of the sequence having fewer nucleotides than about 6 kb, preferably fewer than about 1 kb. A portion or fragment can be used as a probe. Such probes may be labeled with reporter molecules using nick translation, Klenow fill-in
25 reaction, PCR or other methods well known in the art. To optimize reaction conditions and to eliminate false positives, nucleic acid probes may be used in Southern, Northern or in situ hybridizations to determine whether DNA or RNA encoding spingosine kinase is present in a cell type, tissue, or organ.

30

"Probes" may be derived from naturally occurring, recombinant, or chemically synthesized single - or double - stranded nucleic acids or be chemically

synthesized. They are useful in detecting the presence of identical or similar sequences.

5 “Reporter” molecules are those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents which associate with, establish the presence of, and may allow quantification of a particular nucleotide or amino acid sequence.

10 A “signal or leader sequence” can be used, when desired, to direct the polypeptide through a membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous sources by recombinant DNA techniques.

15 Amino acid “substitutions” are conservative in nature when they result from replacing one amino acid with another having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

20 “Standard” is a quantitative or qualitative measurement for comparison. It is based on a statistically appropriate number of normal samples and is created to use as a basis of comparison when performing diagnostic assays, running clinical trials, or following patient treatment profiles.

25 “Stringent conditions” is used herein to mean conditions that allow for hybridization of substantially related nucleic acid sequences. . Such hybridization conditions are described by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, 1989. Generally, stringency occurs within a range from about 5 °C below the melting temperature of the probe to about 20 °C – 25 °C below the melting temperature. As understood by ordinary skilled
30 persons in the art, the stringency conditions may be altered in order to identify or detect identical or related nucleotide sequences. Factors such as the length and nature

(DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.) and the concentration of the salts and other components (e.g. the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered and the hybridization
5 solution may be varied to generate conditions of either low or high stringency.

“Sequence Identity” is known in the art, and is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences, particularly, as determined by the match between strings
10 of such sequences. Sequence identity can be readily calculated by known methods (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence*
15 *Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two sequences, the term is well known to skilled artisans (see, for example, *Sequence Analysis in Molecular Biology*; *Sequence Analysis Primer*; and Carillo, H., and
20 Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988)). Methods commonly employed to determine identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988) or, preferably, in Needleman and Wunsch, *J. Mol. Biol.*, 48: 443-445, 1970, wherein the parameters are as set in version 2 of DNASIS (Hitachi Software
25 Engineering Co., San Bruno, CA). Computer programs for determining identity are publicly available. Preferred computer program methods to determine identity between two sequences include, but are not limited to, GCG program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. *et al.*, *J. Molec. Biol.* 215: 403-410 (1990)). The
30 BLASTX program is publicly available from NCBI (blast@ncbi.nlm.nih.gov) and other sources (*BLAST Manual*, Altschul, S., *et al.*, NCBI NLM NIH Bethesda, MD

20894; Altschul, S., *et al.*, *J. Mol. Bio.* **215**: 403-410 (1990)). Computational Molecular Biology, Lesk, A.M, ed. Unless specified otherwise in the claims, the percent identity for the purpose of interpreting the claims shall be calculated by the Needleman and Wucnsch algorithm with the parameters set in version 2 of DNASIS.

5

“Variants” are polynucleotides or polypeptides that differ from a reference polynucleotide or polypeptide, respectively, but retain essential properties of the reference, preferably, in the case of polypeptides the variant retains the biological activity of the naturally occurring polypeptide. A typical variant of a polynucleotide differs in nucleotide sequence from another reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequences of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, insertions and deletions in the polypeptide encoded by the reference sequences, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions and deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.

25

Description

The invention relates to novel polypeptides and polynucleotides for human sphingosine kinase as described in greater detail below. The invention particularly relates to the three sphingosine kinase homologues: human SKA, human SKB and human SKC. More particularly, human SKA, SKB and SKC having the nucleotide

30

sequences as set out in Figures 2, 5 and 8 for SKA, SKB and SKC, respectively, and variants thereof are provided for herein.

In addition, the polypeptides of the invention include the polypeptides
5 comprising the sequences as set out in Figures 3, 6 and 9 as well as variants of these polypeptides, particularly variants which retain the biological activity of the naturally occurring sphingosine kinase.

Fragments of the polypeptides of the invention may be employed for
10 producing the corresponding full length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full length polypeptides of the invention.

The polynucleotides comprising sequences encoding human SKA, SKB and
15 SKC (or their complement) and variants thereof have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use in the construction of oligomers for PCR, use for chromosome and gene mapping, use in the recombinant production of SKA, SKB and SKC, and use in generation of antisense DNA or RNA, their chemical analogs
20 and the like. Uses of nucleotides encoding SKA, SKB and SKC disclosed herein are exemplary of known techniques and are not intended to limit their use in any technique known to a person of ordinary skill in the art. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide
25 sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of human SKA, SKB and SKC encoding
30 nucleotide sequences may be produced. Some of these will only bear minimal homology to the nucleotide sequence of the known and naturally occurring SKA,

SKB and SKC. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring SKA, SKB and SKC, and all such variations are to be considered as being specifically disclosed.

Although the nucleotide sequences which encode SKA, SKB and SKC, their derivatives or their variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring SKA, SKB and SKC, respectively, under stringent conditions, it may be advantageous to produce nucleotide sequences encoding SKA, SKB and SKC or its derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding SKA, SKB and SKC and/or its derivatives without altering the encoded amino acid sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

Human genes often show considerable actual polymorphism; that is, variation in nucleotide sequence among a fraction of the entire human population. In many cases this polymorphism can result in one or more amino acid substitutions. While some of these substitutions show no demonstrable change in function of the protein, others may produce varying degrees of functional effects. In fact, many natural or artificially produced mutations can lead to expressible human SK proteins. Each of these variants, whether naturally or artificially produced, is considered to be equivalent and specifically incorporated into the present invention.

Nucleotide sequences encoding human SKA, SKB and SKC may be joined to a variety of other nucleotide sequences by means of well established recombinant

DNA techniques (Sambrook J et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor NY; or Ausubel FM et al (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York City).

Useful nucleotide sequences for joining to human SK include an assortment of
5 cloning vectors such as plasmids, cosmids, lambda phage derivatives, phagemids, and
the like. Vectors of interest include expression vectors, replication vectors, probe
generation vectors, sequencing vectors, etc. In general, vectors of interest may
contain an origin of replication functional in at least one organism, convenient
restriction endonuclease sensitive sites, and selectable markers for one or more host
10 cell systems.

Human SK specific hybridization probes are capable of hybridizing with
naturally occurring nucleotide sequences encoding human SKA, SKB and SKC.
Such probes may also be used for the detection of similar sequences and should
15 preferably contain at least 60% nucleotide identity to SK sequence. The
hybridization probes of human SK may be derived from the nucleotide sequence
presented in the Figures for the full length sequence for SKA, SKB and SKC, namely,
Figures 1, 4 and 7, respectively, or from genomic sequences including promoter,
enhancers, introns or 3'-untranslated regions of the native gene. Hybridization probes
20 may be labeled by a variety of reporter molecules using techniques well known in the
art. Preferably, the hybridization probes incorporate at least 15 nucleotides, and
preferably at least 25 nucleotides, of the SK protein. Suitable hybridization probes
would include: consensus fragments, for example, those regions of the human SK
isoforms that are identical, as particularly exemplified in Figure 10.

25

It will be recognized that many deletional or mutational analogs of nucleic
acid sequences for human SK will be effective hybridization probes for human SK
nucleic acid. Accordingly, the invention relates to nucleic acid sequences that
hybridize with such SK encoding nucleic acid sequences under stringent conditions.

30

Stringent conditions will generally allow hybridization of sequence with at

least about 70% sequence identity, more preferably at least about 80-85% sequence identity, even more preferably at least about 90% sequence identity, and most preferably with at least about 95% sequence identity. Hybridization conditions and probes can be adjusted in well-characterized ways to achieve selective hybridization of human-derived probes. Nucleic acid molecules that will hybridize to human SK encoding nucleic acid under stringent conditions can be identified functionally, using methods outlined above, or by using for example the hybridization rules reviewed in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Press, 1989. Without limitation, examples of the uses for hybridization probes include: histochemical uses such as identifying tissues that express human SK; measuring mRNA levels, for instance to identify a sample's tissue type or to identify cells that express abnormal levels of human SK; and detecting polymorphisms in the human SK. RNA hybridization procedures are described in Maniatis et al. *Molecular Cloning, a Laboratory Manual* (Cold Spring Harbor Press, 1989). PCR as described US Patent No's. 4,683,195; 4,800,195; and 4,965,188 provides additional uses for oligonucleotides based upon the nucleotide sequence which encodes the human SK sequences of the invention. Such probes used in PCR may be of recombinant origin, chemically synthesized, or a mixture of both. Oligomers may comprise discrete nucleotide sequences employed under optimized conditions for identification of human SK in specific tissues or diagnostic use. The same two oligomers, a nested set of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for identification of closely related DNA's or RNA's. Rules for designing PCR primers are now established, as reviewed by PCR Protocols, Cold Spring Harbor Press, 1991. Degenerate primers, i.e., preparations of primers that are heterogeneous at given sequence locations, can be designed to amplify nucleic acid sequences that are highly homologous to, but not identical to human SK. Strategies are now available that allow for only one of the primers to be required to specifically hybridize with a known sequence. See, Froman et al., *Proc. Natl. Acad. Sci. USA* 85: 8998, 1988 and Loh et al., *Science* 243: 217, 1989. For example, appropriate nucleic acid primers can be ligated to the nucleic acid sought to be amplified to provide the hybridization partner for one of the primers. In this way, only one of the primers

need be based on the sequence of the nucleic acid sought to be amplified. PCR methods of amplifying nucleic acid will utilize at least two primers. One of these primers will be capable of hybridizing to a first strand of the nucleic acid to be amplified and of priming enzyme-driven nucleic acid synthesis in a first direction.

5 The other will be capable of hybridizing the reciprocal sequence of the first strand (if the sequence to be amplified is single stranded, this sequence will initially be hypothetical, but will be synthesized in the first amplification cycle) and of priming nucleic acid synthesis from that strand in the direction opposite the first direction and towards the site of hybridization for the first primer. Conditions for conducting such

10 amplifications, particularly under preferred stringent hybridization conditions, are well known. See, for example, PCR Protocols, Cold Spring Harbor Press, 1991.

Other means of producing specific hybridization probes for human SK include the cloning of nucleic acid sequences encoding human SK or human SK variants or

15 derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate reporter molecules.

20 It is possible to produce a DNA sequence, or portions thereof, entirely by synthetic chemistry. After synthesis, the nucleic acid sequence can be inserted into any of the many available DNA vectors and their respective host cells using techniques which are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into the nucleotide sequence. Alternately, a portion of

25 sequence in which a mutation is desired can be synthesized and recombined with longer portion of an existing genomic or recombinant sequence.

The nucleotide sequence for human SK can be used in an assay to detect inflammation or disease associated with abnormal levels of SK expression. The

30 cDNA can be labeled by methods known in the art, added to a fluid, cell or tissue sample from a patient, and incubated under hybridizing conditions. After an

incubation period, the sample is washed with a compatible fluid which optionally contains a reporter molecule. After the compatible fluid is rinsed off, the reporter molecule is quantitated and compared with a standard as previously defined.

- 5 A diagnostic test for aberrant expression of SK can accelerate diagnosis and proper treatment of abnormal conditions of SK activity.

 New nucleotide sequences can be assigned to chromosomal subregions by physical mapping. The mapping of new genes or nucleotide sequences provide useful
10 landmarks for investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome, such as ataxia telangiectasia (AT), has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti et al (1988) Nature 336:577-580), any sequences mapping to that area may represent or reveal genes for further
15 investigation. The nucleotide sequence of the subject invention may also be used to detect differences in gene sequence between normal and carrier or affected individuals.

 Nucleotide sequences encoding human SK may be used to produce a purified
20 oligo - or polypeptide using well known methods of recombinant DNA technology. Goeddel (1990, Gene Expression Technology, Methods and Enzymology, Vol. 185, Academic Press, San Diego CA) is one among many publications which teach expression of an isolated nucleotide sequence. The oligopeptide may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from the
25 same species from which the nucleotide sequence was derived or from a different species. Advantages of producing an oligonucleotide by recombinant DNA technology include obtaining adequate amounts of the protein for purification and the availability of simplified purification procedures.

- 30 Cells transformed with DNA encoding human SK may be cultured under conditions suitable for the expression of human kinases and recovery of such peptides

from cell culture. Human SK produced by a recombinant cell may be secreted or may be contained intracellularly, depending on the particular genetic construction used. In general, it is more convenient to prepare recombinant proteins in secreted form.

Purification steps vary with the production process and the particular protein produced. Often an oligopeptide can be produced from a chimeric nucleotide sequence. This is accomplished by ligating the nucleotides from human SK or a desired portion of the polypeptide to a nucleic acid sequence encoding a polypeptide domain which will facilitate protein purification (Kroll DJ et al (1993) DNA Cell Biol. 12:441-53).

10

In addition to recombinant production, fragments of human SK may be produced by direct peptide synthesis using solid-phase techniques (e.g. Stewart et al (1969) Solid-Phase Peptide Synthesis, WH Freeman Co., San Francisco CA; Merrifield J (1963) J Am Chem. Soc. 85:2149-2154). Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Foster City, CA) in accordance with the instructions provided by the manufacturer. Additionally, a particular portion of human SK may be mutated during direct synthesis and combined with other parts of the peptide using chemical methods.

20

Human SK for antibody induction does not require biological activity; however, the protein must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids. They should mimic a portion of the amino acid sequence of the protein and may contain the entire amino acid sequence. An antigenic portion of human SK may be fused to another protein such as keyhole limpet hemocyanin, and the chimeric molecule used for antibody production.

25

Antibodies specific for human SK may be produced by inoculation of an appropriate animal with the polypeptide or an antigenic fragment. An antibody is specific for human SK if it is produced against an epitope of the polypeptide and binds to at least part of the natural or recombinant protein. Antibody production

30

includes not only the stimulation of an immune response by injection into animals, but also analogous processes such as the production of synthetic antibodies, the screening of recombinant immunoglobulin libraries for specific- binding molecules (e.g. Orlandi R et al (1989) PNAS 86:3833-3837, or Huse WD et al (1989) Science 5 256:1275-1281) or the in vitro stimulation of lymphocyte populations. Current technology (Winter G and Milstein C (1991) Nature 349:293-299) provides for a number of highly specific binding reagents based on the principles of antibody formation. These techniques may be adapted to produce molecules which specifically bind SK.

10

An additional embodiment of the subject invention is the use of human SK specific antibodies, inhibitors, ligands or their analogs as bioactive agents to treat inflammation or disease possibly including, but not limited to viral, bacterial or fungal infections; allergic responses; mechanical injury associated with trauma; 15 hereditary diseases; lymphoma or carcinoma; or other conditions which activate the genes of kidney, lung, heart, lymphoid or tissues of the nervous system.

Bioactive compositions comprising agonists, antagonists, receptors or inhibitors of human SK may be administered in a suitable therapeutic dose 20 determined by any of several methodologies including clinical studies on mammalian species to determine maximal tolerable dose and on normal human subjects to determine safe dose. Additionally, the bioactive agent may be complexed with a variety of well established compounds or compositions which enhance stability or pharmacological properties such as half-life. It is contemplated that the therapeutic, 25 bioactive composition may be delivered by intravenous infusion into the bloodstream or any other effective means which could be used for treating problems involving aberrant expression of the EDG-7 gene.

The examples below are provided to illustrate the subject invention. These 30 examples are provided by way of illustration and are not included for the purpose of limiting the invention.

Example 1**Cloning of PSKA****5 A. Diagnostic PCR of various templates for the presence of human SKA cDNA**

The following pairs of primers were designed:

10 5' end Primers

SK1F 5' AAC CCG CGC GGC GCA AGG GCA AGG C 3'

SK2F 5' AAG GGC AAG GCC TTG CAG CTC TTC C 3'

3' end Primers

15 SK1R 5' CAG GCC GCT CCA TGA GCC CGT TCA C 3'

SK2R 5' GCA TCA GCC CGT CTC CAG ACA TGA 3'

Using these primers, PCR was conducted under the conditions as set out below on the templates from the following sources:

20

Template source DNA of cDNA Libraries prepared from Human Lung

Fibroblasts WI-38 (Origene Technologies Inc., Cat. No. DLH-102), Human Liver

(Origene Technologies Inc., Cat. No. DLH-100), cultured human Jurkat T-cells

(Origene Technologies Inc., Cat. No. DLH-115), HeLa cultured cells (Origene

25 Technologies Inc., Cat. No. DLH-103), Human kidney proximal tubules (ATCC),

HeLa cultured cells (Invitrogen, Cat. No. A550-26), Human Lung (Clonotech, Cat.

No.7114-1), HeLa cultured cells (Clonotech, Cat. No. HL5013a), human small

intestine (Clonotech, Cat. No. HL1133a). Each template was amplified with each pair

of primers under the following condition of PCR amplification by using Expand TM

30 PCR kit of Boehringer Mannheim (Catalogue no. 1681-842).

Each reaction contained the following reagents:

- 2 µl of 10x PCR Buffer 3
- 0.4 µl of 25mM dNTP mix
- 0.6 µl of Primer SKF1 or SKF2 (10pm/µl)
- 5 0.6 µl of Primer SKR1 or SKR2 (10pm/µl)
- 0.3µl of Enzyme (3unit)
- 15.1 µl water
- 1 µl DNA

10 PCR conditions:

- Incubate: 94°C for 2 min
- 30 cycles: 94°C for 1 min
- 62°C for 1 min
- 68°C for 30 sec
- 15 Incubate: 68°C for 8 min
- Hold: 4°C

- A 200 bp (approximately) DNA fragment was amplified from all templates except
- 20 Origene's HeLa cDNA library and Clontech's small intestine cDNA library.
- The cDNA library from cultured HeLa cells (Invitrogen) appeared to contain PSKA clones.

25 **B. PCR Screening of HeLa cDNA Library**

- 10 000 (10K) clone pools from cDNA library from cultured HeLa cells (Invitrogen, Cat. No. A550-26): Approximately, ten thousand clones were grown on an agar plate, scraped and re-suspended in one ml of 2X YT + 20% glycerol. Overall,
- 30 610 pools (10K) were prepared. Equal proportions of twelve 10K pools were mixed to prepare 120K pools. In all, there were fifty one 120K pools. All pools are kept as

frozen stocks at 80°C. For PCR screening, a small portion of frozen stock was re-suspended in 100 µl of 2X YT + 20% glycerol and used as template.

C. Screening of 120K and 10K bacterial

5

All fifty one 120K bacterial pools and 10K pools of positive 120K pools were amplified under the following condition of PCR amplification by using Expand™ PCR system from Boehringer Mannheim (Catalogue no. 1681-842) with the following pair of primers.

10

SK1F 5' AAC CCG CGC GGC GCA AGG GCA AGG C
SK1R 5' CAG GCC GCT CCA TGA GCC CGT TCA C 3'

Each reaction contained the following reagents:

15

2 µl of 10x PCR Buffer 3
0.4 µl of 25mM dNTP mix
0.6 µl of Primer SKF1 (10pm/µl)
0.6 µl of Primer SKR1 (10pm/µl)
20 0.3 µl of Enzyme (3unit)
15.1 µl water
1 µl DNA

PCR conditions:

25 Incubate: 94°C for 2 min
30 cycles: 94°C for 40 sec
 60°C for 40 sec
 68°C for 40 sec
Incubate: 68°C for 8 min
30 Hold: 4°C

Majority of 120K bacterial pools was found positive indicating that PSKA is an abundantly expressed gene. Four 10 K pools (62, 64, 74, 403, and 404 from selected positive 120K pools) were found positive.

5

D. PCR screening of sub-pools of 10K pool #403:

The bacterial colonies were grown from the positive 10K pool #403 on the agar plate. Plugs containing 300 – 1000 bacterial colonies were lifted from the agar plate. The bacterial colonies were re-suspended into 500 ul of 2XYT + 20% glycerol. The bacterial re-suspensions were used as template to amplify with the following pair of primers.

SK1F 5' AAC CCG CGC GGC GCA AGG GCA AGG C
15 SK1R 5' CAG GCC GCT CCA TGA GCC CGT TCA C 3'

Each reaction contained the following reagents:

2 µl of 10x PCR Buffer 3
20 0.4 µl of 25mM dNTP mix
0.6 µl of Primer SKF1 (10pm/µl)
0.6 µl of Primer SKR1 (10pm/µl)
0.3 µl of Enzyme (3unit)
15.1 µl water
25 1 µl DNA

PCR conditions:

Incubate: 94°C for 2 min
30 cycles: 94°C for 40 sec
30 60°C for 40 sec
 68°C for 40 sec

Incubate: 68°C for 8 min

Hold: 4°C

- 5 Several positive sub-pools were identified. Sub-pool #403-42 was used further to isolate PSKA clone.

E. Hybridization screening of sub-pool # 403-42

- 10 Bacterial colonies were grown from sub-pool #403-42 on the agar plate and were transferred to nylon filters. Filter hybridization was carried out using 200 bp DNA fragment (amplified by SK1F and SK1R from template 10K pool no. 62) as probe. The following hybridization conditions were employed:

- 15 5X SSPE

5X Denharts solution (1% Ficoll, 1% Polyvinylpyrrolidone, 1% BSA)

25µg/ml fish sperm DNA

Hybridise at 65°C overnight.

- 20

The filters were washed 2 times in 2X SSPE and 0.1% SDS at room temperature for 30 minutes each, then 2 times in 2XSSPE and 0.1% SDS at 50°C for 20 minutes each and finally two times in 0.1XSSPE and 0.1% SDS.

- 25 One positive plug 403-42.1 was identified.

F. PCR screening of plug #403-42.1

- 30 Bacterial colonies from plug #403-42.1 were grown on the agar plate, picked and re-suspended into 100 µl of 2XYT + 20% glycerol. The bacterial re-suspensions were used as template to amplify with the following pair of primers.

SK1F 5' AAC CCG CGC GGC GCA AGG GCA AGG C
SK1R 5' CAG GCC GCT CCA TGA GCC CGT TCA C 3'

5 Each reaction contained the following reagents:

2 µl of 10x PCR Buffer 3
0.4 µl of 25mM dNTP mix
0.6 µl of Primer SKF1 (10pm/µl)
10 0.6 µl of Primer SKR1 (10pm/µl)
0.3 µl of Enzyme (3unit)
15.1 µl water
1 µl DNA

15 PCR conditions:

Incubate: 94°C for 2 min
30 cycles: 94°C for 40 sec
 60°C for 40 sec
 68°C for 40 sec
20 Incubate: 68°C for 8 min

Hold: 4°C

25 A single isolated bacterial colony (403-42.1-P1C6-P1C3) was identified as a positive colony to contain PSKA cDNA. The plasmid and clone was given ID as pc3-PSKA#403-1. The plasmid DNA was prepared using midi-plasmid preparation kit (Qiagen, catalogue no. 12245) to use for sequencing and transfections.

Example 2**Cloning of SKB****5 A. Screening of 120K bacterial pools and 10K bacterial**

All fifty one 120K bacterial pools were amplified under the following condition of PCR amplification by using Expand™ PCR system from Boehringer Mannheim (Catalogue no. 1681-842) with the following pair of primers.

10

PSKB-C4F2 5' TGC AAA TCT CTA GAA GAT GAC GGT G 3'

PSKB-C4R3 5' TAT ACT CAA ACT ACT GGT CTC TCC AAG 3'

Each reaction contained the following reagents:

15

2 µl of 10x PCR Buffer 3

0.4 µl of 25mM dNTP mix

0.6 µl of Primer PSKB-C4F2 (10pm/µl)

0.6 µl of Primer PSKB-C4R3 (10pm/µl)

20

0.3 µl of Enzyme (3unit)

15.1 µl water

1 µl DNA

PCR conditions:

25

Incubate: 94°C for 2 min

30 cycles: 94°C for 1 min

62°C for 1 min

68°C for 1 min

Incubate: 68°C for 8 min

30

Hold: 4°C

A DNA fragment of approximately 500bp was amplified from four 120K bacterial pools.

5 B. Screening of 10K bacterial pools

10K pools of positive three 120K pools were amplified under the following condition of PCR amplification by using Expand™ PCR system from Boehringer Mannheim (Catalogue no. 1681-842) with the following pair of primers.

10

PSKB-C4F2	5' TGC AAA TCT CTA GAA GAT GAC GGT G 3'
PSKB-C4R3	5' TAT ACT CAA ACT ACT GGT CTC TCC AAG 3'

Each reaction contained the following reagents:

15

2 µl of 10x PCR Buffer 3
0.4 µl of 25mM dNTP mix
0.6 µl of Primer PSKB-C4F2 (10pm/µl)
0.6 µl of Primer PSKB-C4R3 (10pm/µl)
20 0.3 µl of Enzyme (3unit)
15.1 µl water
1 µl DNA

PCR conditions:

25	Incubate:	94°C for 2 min
	32 cycles:	94°C for 1 min 58°C for 40 sec 68°C for 40 sec
	Incubate:	68°C for 8 min
30	Hold:	4°C

Two 10K bacterial pools (308 and 532) were found positive.

C. Isolation of PSKB clone from 10K bacterial pool #532 by PCR Screening

5

The following three steps and three rounds of PCR were used to isolate individual positive clone of PSKB cDNA from 10K bacterial pool #532.

- 10 1. 10K bacterial pool #532 was plated on agar plates. 100-500 colonies were scraped in sub-pool and re-suspended in 100 µl of 2XYT + 20% glycerol. The bacterial re-suspensions were used as template for PCR screening.
2. The positive sub-pool of 100-500 bacterial colonies was plated on agar plates. 20-50 colonies were scraped in sub-pool and re-suspended in 100 µl of 2XYT + 20% glycerol. The bacterial re-suspensions were used as template for PCR screening.
- 15 3. The positive sub-pool of 20-50 bacterial colonies was plated on agar plates. The individual bacterial colonies were scraped and re-suspended in 100 µl of 2XYT + 20% glycerol. The bacterial re-suspensions were used as template for PCR screening.

- 20 The PCR screening was done by using Expand TM PCR system from Boehringer Mannheim (Catalogue no. 1681-842) with the following pair of primers.

PSKB-C4F2	5' TGC AAA TCT CTA GAA GAT GAC GGT G 3'
PSKB-C4R3	5' TAT ACT CAA ACT ACT GGT CTC TCC AAG 3'

25

Each reaction contained the following reagents:

- | | |
|----|--------------------------------------|
| | 2 µl of 10x PCR Buffer 3 |
| | 0.4 µl of 25mM dNTP mix |
| 30 | 0.6 µl of Primer PSKB-C4F2 (10pm/µl) |
| | 0.6 µl of Primer PSKB-C4R3 (10pm/µl) |

0.3 µl of Enzyme (3unit)

15.1 µl water

1 µl DNA

5 PCR conditions:

Incubate: 94°C for 2 min

30 cycles: 94°C for 1 min

58°C for 40 sec

68°C for 40 sec

10 Incubate: 68°C for 8 min

Hold: 4°C

15 Two colonies (532 - P1A9 - P1G1 – P1E4 and 532 - P1A9 - P1G1 – P1E9) were found positive. They were given ID of pc3-PSKB#532-1 and pc3-PSKB#532-2. The plasmid DNA was prepared using mini-plasmid preparation kit (Qiagen, catalogue no. 12245) to use for sequencing and transfections.

20

Example 3

Cloning of SKC

A. Screening of 120K bacterial pools and 10K bacterial

25 All fifty one 120K bacterial pools were amplified under the following condition of PCR amplification by using Expand™ PCR system from Boehringer Mannheim (Catalogue no. 1681-842) with the following pair of primers.

PSKC-F2 5' TTA ACA TAG ACA AAT ACG ACG GCA TCG 3'

30 PSKC-R1 5' ACA CAT CCA TGG CCA GCG AGT CC 3'

Each reaction contained the following reagents:

- 2 µl of 10x PCR Buffer 3
- 0.4 µl of 25mM dNTP mix
- 5 0.6 µl of Primer PSKC-F2 (10pm/µl)
- 0.6 µl of Primer PSKC-R1 (10pm/µl)
- 0.3 µl of Enzyme (3unit)
- 15.1 µl water
- 1 µl DNA

10

PCR conditions:

- Incubate: 94°C for 2 min
- 30 cycles: 94°C for 40 sec
- 58°C for 40 sec
- 15 68°C for 40 sec
- Incubate: 68°C for 8 min
- Hold: 4°C

- 20 A DNA fragment of approximately 250bp was amplified from ten 120K bacterial pools.

B. Screening of 10K bacterial pools

- 25 10K pools of the four positive 120K pools were amplified under the following condition of PCR amplification by using Expand TM PCR system from Boehringer Mannheim (Catalogue no. 1681-842) with the following pair of primers.

- PSKC-F2 5' TTA ACA TAG ACA AAT ACG ACG GCA TCG 3'
- 30 PSKC-R1 5' ACA CAT CCA TGG CCA GCG AGT CC 3'

Each reaction contained the following reagents:

- 2 µl of 10x PCR Buffer 3
- 0.4 µl of 25mM dNTP mix
- 5 0.6 µl of Primer PSKC-F2 (10pm/µl)
- 0.6 µl of Primer PSKC-R1 (10pm/µl)
- 0.3 µl of Enzyme (3unit)
- 15.1 µl water
- 1 µl DNA

10

PCR conditions:

- Incubate: 94°C for 2 min
- 30 cycles: 94°C for 40 sec
- 58°C for 40 sec
- 15 68°C for 40 sec
- Incubate: 68°C for 8 min
- Hold: 4°C

20

Three 10K bacterial pools (64, 320 and 330) were found positive.

C. Isolation of PSKC clone from 10K bacterial pool #330 by PCR Screening

25

The following three steps and three rounds of PCR were used to isolate individual positive clone of PSKC cDNA from 10K bacterial pool #330.

- 4. 10K bacterial pool #330 was plated on agar plates. 100-500 colonies were scraped
- 30 in sub-pool and re-suspended in 100 µl of 2XYT + 20% glycerol. The bacterial re-suspensions were used as template for PCR screening.

5. The positive sub-pool of 100-500 bacterial colonies was plated on agar plates. 20-50 colonies were scraped in sub-pool and re-suspended in 100 µl of 2XYT + 20% glycerol. The bacterial re-suspensions were used as template for PCR screening.
6. The positive sub-pool of 20-50 bacterial colonies was plated on agar plates. The individual bacterial colonies were scraped and re-suspended in 100 µl of 2XYT + 20% glycerol. The bacterial re-suspensions were used as template for PCR screening.

- 10 The PCR screening were done by using Expand TM PCR system from Boehringer Mannheim (Catalogue no. 1681-842) with the following pair of primers.

PSKC-F2	5' TTA ACA TAG ACA AAT ACG ACG GCA TCG 3'
PSKC-R1	5' ACA CAT CCA TGG CCA GCG AGT CC 3'

15

Each reaction contained the following reagents:

- 2 µl of 10x PCR Buffer 3
- 0.4 µl of 25mM dNTP mix
- 20 0.6 µl of Primer PSKC-F2 (10pm/µl)
- 0.6 µl of Primer PSKC-R1 (10pm/µl)
- 0.3 µl of Enzyme (3unit)
- 15.1 µl water
- 1 µl DNA

25

PCR conditions:

- | | |
|------------|-----------------|
| Incubate: | 94°C for 2 min |
| 30 cycles: | 94°C for 40 sec |
| | 58°C for 40 sec |
| 30 | 68°C for 40 sec |
| Incubate: | 68°C for 8 min |

Hold: 4°C

Two colonies (330 – P1G3 – P1B8 – P2A9 and 330 – P1G3 – P4E10– P1B12) were found positive. They were given ID of pc3-PSKC#330-1 and pc3-PSKC#330-2. The plasmid DNA was prepared using mini-plasmid preparation kit (Qiagen, catalogue no. 12245) to use for sequencing and transfections.

10 Example 4 Phosphorylation activity of Human Sphingosine Kinase

A) Protocol of Phosphorylation Assay using Swiss 3T3 and 293-EBNA cells— Phosphate label

15

- 1) Swiss 3T3 cells were washed with PBS and harvested by scraping in 1 ml of protein buffer [0.1 M Tris-HCl, pH 7.4 containing 20% glycerol (v/v), 1mM mercaptoethanol, 1 mM EDTA, 1 mM Na₃VO₄ (Sigma, cat # S6508), 15 mM NaF, 10µg/ml leupeptin (Sigma, cat # L2023) and aprotinin (Sigma, cat# A6279), 1 mM PMSF and 0.5 mM 4-deoxypyridoxine(Sigma, cat # D0501)] (as described in Edsall et al., 1997).
- 2) Methods were taken from Edsall et al., 1997, with the following exceptions: once cells were lysed by freeze-thawing three times, the cytosolic fraction was prepared by centrifugation at 13,000 x g for 20 min at 4°C.
- 3) The phosphorylation reaction included, 80 µl of cytosolic fraction with 10 µl of sphingosine (Calbiochem, cat # 219535-S) (100 µM dissolved in a 4mg/ml solution of BSA). The reactions were started by adding 10 µl of [γ ³³P]-ATP (10-20 µCi, 10 mM) (Amersham cat # AH 9968) prepared in 100 mM MgCl₂. Samples were incubated at 37°C for one hour.
- 4) Lipids were extracted with 800 µl chloroform:methanol:concentrated HCl (100:200:1). Samples were vortexed and phases were separated by adding 240 µl

of chloroform and 240 µl of 2M KCl (as described in Olivera et al., 1994).

Samples were vortexed and centrifuged at 11,000 x g for 5 min.

- 5) Lipids found in the organic phase were spotted on a TLC silica gel plate and run in the following solvent system: chloroform:methanol:acetic acid:water (60:30:5:5). A sphingosine 1-phosphate (S 1-P) (Sigma, cat #S-9666) and sphingosine (Sph) (standard was run alongside all experimental samples as well as a reaction tube containing no sphingosine as a negative control.
- 6) The sphingosine 1-phosphate and sphingosine standards were visualized using a KMnO₄ stain (100 ml H₂O: 4g KMnO₄, 4g NaHCO₃). TLC plates were exposed to a phosphor screen overnight.
- 7) S 1-P bands were visualized and quantified with the Storm Phosphoimager (Molecular Dynamics, Sunnyvale, CA).

B) Transient transfection protocol for 293-EBNA

15

Day 1.

- 1) 100 mm plates of 293-EBNA with a confluency of 50-80% were used for transfection.
- 2) SKA, SKB, SKC and pcDNA3 (4 µg) DNA samples were diluted in 750 µl of DMEM/F12 (serum-free media) and 20 µl Plus Reagent (Lipofectamine Plus Kit, Life Technologies Cat. 10964-013), and incubated at room temperature for 15 min.
- 3) 30 µl Lipofectamine Reagent (Lipofectamine Plus Kit) was diluted in 750 µl DMEM/F12. The diluted Lipofectamine was then combined with the DNA/Plus mixture and incubated at RT for 15 min.
- 4) The 293-EBNA plates were washed once with PBS, and 5 ml DMEM/F12 was added to each plate.
- 5) DNA/Plus/Lipofectamine mixture was added to each plate of 293-EBNA cells. The plates were left for 3 hr at 37°C in a 5% CO₂ incubator.
- 6) The transfection medium was replaced with DMEM/F12 containing 10% FBS to recover overnight.

Day 3.

Media was removed and stored at -80°C . Cells were washed once with PBS and were harvested by scrapping cells in 1 ml of protein buffer (described above). Cells
5 were lysed by freeze-thawing three times. Cytosolic fractions were obtained by centrifugation at $13,000 \times g$ for 20 min at 4°C . Pellets of cell debris resulting from this spin was stored at -80°C for later use. Cytosolic protein preparations were stored at -80°C for future use.

10 **C) Phosphorylation Assay using Three Fractions of SKA, SKB and SKC.**

i) Cytosolic Fraction.

The phosphorylation assay was performed as outlined above, except 5 μl of Triton X-100 was added to each reaction tube.

15 *ii) Debris Fraction*

Each pellet consisting of cellular debris was re-suspended in 80 μl of protein buffer. The suspension was sonicated. This prep was used for the phosphorylation assay which was as outlined above in the cytosolic fraction.

iii) Cell Media

20 The cell media was dried down in a refrigerated speed-vac. The pellet was re-suspended in 80 μl of protein buffer. This preparation was used for the phosphorylation assay which was as outlined above in the cytosolic fraction.

25 **D) Protocol of Phosphorylation Assay using 293-EBNA cells—Compound Label**

Enzyme preparations of SKA and pcDNA3 were used in phosphorylation assays.

The protocol was the same as mentioned above in A.3-7 with a few exceptions:

i) 5 μl of Triton X-100 was added to each reaction tube and ii) ^{33}P -ATP was not used, only "cold" ATP was used in each reaction (10 mM in 100 mM MgCl_2).

30

The results for the above phosphorylation assays indicated that SKA was involved in phosphorylating sphingosine to form sphingosine 1-phosphate. In particular, as indicated in Figure 11, SKA was shown to be involved in phosphorylating sphingosine whereas the tests did not exemplify phosphorylation by the cloned SKB and SKC genes.

Example 5 Antisense analysis

Knowledge of the correct, complete cDNA sequence of human SK enables its use as a tool for antisense technology in the investigation of gene function. Oligonucleotides, cDNA or genomic fragments comprising the antisense strand of SK are used either in vitro or in vivo to inhibit expression of the mRNA. Such technology is now well known in the art, and antisense molecules can be designed at various locations along the nucleotide sequences. By treatment of cells or whole test animals with such antisense sequences, the gene of interest is effectively turned off. Frequently, the function of the gene is ascertained by observing behavior at the intracellular, cellular, tissue or organismal level (e.g., lethality, loss of differentiated function, changes in morphology, etc.).

In addition to using sequences constructed to interrupt transcription of a particular open reading frame, modifications of gene expression is obtained by designing antisense sequences to intron regions, promoter/enhancer elements, or even to trans-acting regulatory genes. Similarly, inhibition is achieved using Hogeboom base-pairing methodology, also known as "triple helix" base pairing.

Example 6 Expression of Human SK

Expression of human SK is accomplished by subcloning the cDNAs into appropriate expression vectors and transfecting the vectors into analogous expression hosts for example E.Coli. In a particular case, the vector is engineered such that it contains a promoter for β -galactosidase, upstream of the cloning site, followed by

sequence containing the amino-terminal Met and the subsequent 7 residues of β -galactosidase. Immediately following these eight residues is an engineered bacteriophage promoter useful for artificial priming and transcription and for providing a number of unique endonuclease restriction sites for cloning.

5

Induction of the isolated, transfected bacterial strain with IPTG using standard methods produces a fusion protein corresponding to the first seven residues of β -galactosidase, about 15 residues of "linker", and the peptide encoded within the cDNA. Since cDNA clone inserts are generated by an essentially random process, there is one chance in three that the included cDNA will lie in the correct frame for proper translation. If the cDNA is not in the proper reading frame, it is obtained by deletion or insertion of the appropriate number of bases using well known methods including in vitro mutagenesis, digestion with exonuclease III or mung bean nuclease, or the inclusion of an oligonucleotide linker of appropriate length.

15

The human SK cDNA is shuttled into other vectors known to be useful for expression of protein in specific hosts. Oligonucleotide primers containing cloning sites as well as a segment of DNA (about 25 bases) sufficient to hybridize to stretches at both ends of the target cDNA is synthesized chemically by standard methods. These primers are then used to amplify the desired gene segment by PCR. The resulting gene segment is digested with appropriate restriction enzymes under standard conditions and isolated by gel electrophoresis. Alternately, similar gene segments are produced by digestion of the cDNA with appropriate restriction enzymes. Using appropriate primers, segments of coding sequence from more than one gene are ligated together and cloned in appropriate vectors. It is possible to optimize expression by construction of such chimeric sequences.

25

Suitable expression hosts for such chimeric molecules include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells, insect cells such as Sf9 cells, yeast cells such as *Saccharomyces cerevisiae*, and bacteria such as *E. coli*. For each of these cell systems, a useful expression vector

30

also includes an origin of replication to allow propagation in bacteria and a selectable marker such as the β -lactamase antibiotic resistance gene to allow plasmid selection in bacteria. In addition, the vector may include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected eukaryotic
5 host cells. Vectors for use in eukaryotic expression hosts require RNA processing elements such as 3' polyadenylation sequences if such are not part of the cDNA of interest.

Additionally, the vector contains promoters or enhancers which increase gene
10 expression. Such promoters are host specific and include MMTV, SV40, and metallothionine promoters for CHO cells; trp, lac, tac and T7 promoters for bacterial hosts; and alpha factor, alcohol oxidase and PGH promoters for yeast. Transcription enhancers, such as the rous sarcoma virus enhancer, are used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through standard
15 culture methods, large quantities of recombinantly produced human SK are recovered from the conditioned medium and analyzed using chromatographic methods known in the art. For example, human SK can be expressibly cloned into the expression vector pcDNA3. This product can be used to transform, for example, HEK293 or COS by methodology standard in the art. Specifically, for example, using Lipofectamine
20 (Gibco BRL catalog no. 18324-020) mediated gene transfer.

Example 7

Isolation of Recombinant SK

Human SK is expressed as a chimeric protein with one or more additional
25 polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle
30 WA). The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen) between the purification domain and the human SK

sequence is useful to facilitate expression of human SK.

Example 8

Production of SK Specific Antibodies

5 Two approaches are utilized to raise antibodies to human SK, and each approach is useful for generating either polyclonal or monoclonal antibodies. In one approach, denatured protein from reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits using standard protocols; about 100 micrograms are adequate for immunization of a
10 mouse, while up to 1 mg might be used to immunize a rabbit. For identifying mouse hybridomas, the denatured protein is radioiodinated and used to screen potential murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg is sufficient for labeling and screening of several thousand clones.

15

 In the second approach, the amino acid sequence of an appropriate human SK domain, as deduced from translation of the cDNA, is analyzed to determine regions of high antigenicity. Oligopeptides comprising appropriate hydrophilic regions are synthesized and used in suitable immunization protocols to raise antibodies. Analysis
20 to select appropriate epitopes is described by Ausubel FM et al (supra). The optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the protein is in its natural conformation.

25 Typically, selected peptides, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH; Sigma, St. Louis MO) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel FM et al, supra). If necessary, a cysteine is introduced at the N-terminus of the peptide to permit
30 coupling to KLH. Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding

the peptide to plastic, blocking with 1% bovine serum albumin, reacting with antisera, washing and reacting with labeled (radioactive or fluorescent), affinity purified, specific goat anti-rabbit IgG.

5 Hybridomas are prepared and screened using standard techniques.

Hybridomas of interest are detected by screening with labeled human SK to identify those fusions producing the monoclonal antibody with the desired specificity. In a typical protocol, wells of plates (FAST; Becton-Dickinson, Palo Alto CA) are coated during incubation with affinity purified, specific rabbit anti-mouse (or suitable
10 antispecies Ig) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA, washed and incubated with supernatants from hybridomas. After washing the wells are incubated with labeled human SK at 1 mg/ml. Supernatants with specific antibodies bind more labeled human SK than is detectable in the background. Then clones producing specific antibodies are expanded and subjected to two cycles of
15 cloning at limiting dilution. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from mouse ascetic fluid by affinity chromatography on Protein A. Monoclonal antibodies with affinities of at least 10^8 M^{-1} , preferably 10^9 to 10^{10} or stronger, are typically made by standard procedures as described in Harlow and Lane (1988) Antibodies: A Laboratory
20 Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; and in Goding (1986) Monoclonal Antibodies: Principles and Practice, Academic Press, New York City, both incorporated herein by reference.

Example 9 **Diagnostic Test Using Human SK Specific**
25 **Antibodies**

Particular Human SK antibodies are useful for investigating signal transduction and the diagnosis of infectious or hereditary conditions which are characterized by differences in the amount or distribution of human SK or downstream products of an active signaling cascade.

Diagnostic tests for human SK include methods utilizing antibody and a label to detect human SK in human body fluids, membranes, cells, tissues or extracts of such. The polypeptides and antibodies of the present invention are used with or without modification. Frequently, the polypeptides and antibodies are labeled by joining them, either covalently or noncovalently, with a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and have been reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, chromogenic agents, magnetic particles and the like. Patents teaching the use of such labels include US Patent No's. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in US Patent No.4,816,567, Incorporated herein by reference.

15 A variety of protocols for measuring soluble or membrane-bound human SK, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-
20 interfering epitopes on human SK is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, DE et al (1983, J Exp. Med. 158:1211f).

25 **Example 10** **Purification of Native Human SK Using Specific**
 Antibodies

Native or recombinant human SK is purified by immunoaffinity chromatography using antibodies specific for human SK. In general, an immunoaffinity column is constructed by covalently coupling the anti-TRH antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway NJ). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or
5 chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

10

Such immunoaffinity columns are utilized in the purification of human SK by preparing a fraction from cells containing human SK in a soluble form. This preparation is derived by solubilization of whole cells or of a subcellular fraction obtained via differential centrifugation (with or without addition of detergent) or by
15 other methods well known in the art. Alternatively, soluble human SK containing a signal sequence is secreted in useful quantity into the medium in which the cells are grown.

Example 11

Drug Screening

20

This invention is particularly useful for screening therapeutic compounds by using human SK or binding fragments thereof in any of a variety of drug screening techniques. For example, human SK activity can be measured using any of a variety of appropriate functional assays in which activation of the kinase results in an
25 observable change in the level of a particular product. Thus, the present invention provides methods of screening for drugs or any other agents which are affected by human SK.

Alternatively, the polypeptide or fragment employed in such a test is either free in solution, affixed to a solid support, borne on a cell surface or located
30 intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells (or membrane preparations therefrom) which are stably transformed with

recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells. One measures, for example, the formation of a phosphorylated product and compares that with a control.

5 **Example 12** **Rational Drug Design**

Herein, the goal of rational drug design is to produce structural analogs of biologically active lipids of interest or of small molecules with which they interact, agonists, antagonists, or inhibitors.

10

In one approach, the three-dimensional structure of a protein of interest, or of a protein-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to
15 determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide is gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design efficient inhibitors. Useful examples of rational drug design includes molecules which have improved activity or stability as shown by Braxton S and Wells JA (1992, 20 Biochemistry 31:7796-7801) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda SB et al (1993 J Biochem 113:742-46), incorporated herein by reference.

25

Example 13 **Use and Administration of Antibodies, Inhibitors, or Antagonists**

Antibodies, inhibitors, or antagonists of human SK (or other treatments to limit signal transduction, LST) provide different effects when administered therapeutically. LSTs are formulated in a nontoxic, inert, pharmaceutically
30 acceptable aqueous carrier medium preferably at a pH of about 5 to 8, more preferably 6 to 8, although pH may vary according to the characteristics of the

antibody, inhibitor, or antagonist being formulated and the condition to be treated. Characteristics of LSTs include solubility of the molecule, half-life and antigenicity/immunogenicity. These and other characteristics aid in defining an effective carrier.

5

LSTs are delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes. The particular formulation, exact dosage, and route of administration is determined by the attending physician and varies according to each specific situation.

10

Such determinations are made by considering multiple variables such as the condition to be treated, the LST to be administered, and the pharmacokinetic profile of a particular LST. Additional factors which are taken into account include severity of the disease state, patient's age, weight, gender and diet, time and frequency of LST administration, possible combination with other drugs, reaction sensitivities, and tolerance/response to therapy. Long acting LST formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular LST.

15

20

Normal dosage amounts vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see US Patent Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art employ different formulations for different LSTs. Administration to cells such as nerve cells necessitates delivery in a manner different from that to other cells such as vascular endothelial cells.

25

It is contemplated that abnormal signal transduction, trauma, or diseases which trigger humans SK activity are treatable with LSTs. These conditions or

30

diseases are specifically diagnosed by the tests discussed above, and such testing should be performed in suspected cases of viral, bacterial or fungal infections: allergic responses; mechanical injury associated with trauma; hereditary diseases; lymphoma or carcinoma; or other conditions which activate the genes of lymphoid or neuronal tissues.

All publications and patent applications mentioned herein are incorporated by reference for the purpose of describing the methodologies, cell lines and vectors, among other things. However, nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure, for example, by virtue of prior invention.

Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments.

Claims

1. An isolated polynucleotide comprising a sequence encoding human sphingosine kinase as selected from the group consisting of:
 - 5 (a) human sphingosine kinase A or variants thereof;
 - (b) human sphingosine kinase B or variants thereof; and
 - (c) human sphingosine kinase C or variants thereof.
- 10 2. The isolated polynucleotide of claim 1 wherein said sequence encodes human sphingosine kinase A or variants thereof.
3. The isolated polynucleotide of claim 2 wherein said sequence encodes the sequence of Figure 3.
- 15 4. The isolated polynucleotide of claim 1 wherein said sequence encodes human sphingosine kinase B or variants thereof.
5. The isolated polynucleotide of claim 4 wherein said sequence encodes the sequence of Figure 6.
- 20 6. The isolated polynucleotide of claim 1 wherein said sequence encodes human sphingosine kinase C or variants thereof.
7. The isolated polynucleotide of claim 6 wherein said sequence encodes the sequence of Figure 9.
- 25 8. An isolated polynucleotide sequence comprising a complement of claim 1.
9. A composition containing the isolated polynucleotide sequence of claim 8 and an acceptable excipient.
- 30

10. An expression construct containing the isolated polynucleotide of claim 1.
11. A host cell containing the expression vector of claim 10.
- 5 12. A method for making a purified polypeptide comprising the amino acid sequence for human sphingosine kinase wherein the method comprises the steps of culturing a host cell of claim 11 in suitable conditions to express said polypeptide and isolating and purifying said expressed polypeptide.
- 10 13. A purified polypeptide comprising the amino acid sequence for human sphingosine kinase prepared by the method of claim 12.
14. A method of screening a compound for determining the capability of said compound to inhibit or activate human sphingosine kinase activity, which method
15 comprises:
 - contacting a host cell of claim 11 with said compound; and
 - measuring the inhibition or activation of human sphingosine kinase activity.

1/22

Figure 1 Full-length human PSKA cDNA.

GAGGTTATGGATCCAGCGGGCGGCCCCCGGGGCGTGCTCCCGCGGCCCTGCCGCGTGCTG
-----+-----+-----+-----+-----+-----+-----+
1 CTCCAATACCTAGGTCGCCCCGCCGGGGCCCCGCACGAGGGCGCCGGGACGGCGCACGAC 60

GTGCTGCTGAACCCGCGCGGGCGGCAAGGGCAAGGCCTTGACGCTCTTCCGGAGTCACGTG
-----+-----+-----+-----+-----+-----+-----+
61 CACGACGACTTGGGCGCGCCGCGCTTCCCGTTCCGGAACGTCGAGAAGGCCTCAGTGCAC 120

CAGCCCCCTTTTGGCTGAGGCTGAAATCTCCTTCACGCTGATGCTCACTGAGCGGCGGAAC
-----+-----+-----+-----+-----+-----+-----+
121 GTCGGGGAAAACCGACTCCGACTTTAGAGGAAGTGCAGTACGAGTGAAGTGCAGCGCCTTG 180

CACGCGCGGGAGCTGGTGCGGTCCGAGGAGCTGGGCGGCTGGGACGCTCTGGTGGTCATG
-----+-----+-----+-----+-----+-----+-----+
181 GTGCGCGCCCTCGACCAGCCAGCCTCCTCGACCCGGCGACCCTGCGAGACCACCAGTAC 240

TCTGGAGACGGGCTGATGCACGAGGTGGTGAACGGGCTCATGGAGCGGCCTGACTGGGAG
-----+-----+-----+-----+-----+-----+-----+
241 AGACCTCTGCCCGACTACGTGCTCCACCCTTGCCCGAGTACCTCGCCGGACTGACCCTC 300

ACCGCCATCCAGAAaCCCCTGTGTATCCTCCAGCAGGCTCTGGCAACGCGCTGGCAGCT
-----+-----+-----+-----+-----+-----+-----+
301 TGGCGGTAGGTCTTtGGGGACACATAGGAGGGTCGTCCGAGACCGTTGCGCGACCGTCA 360

TCCTTGAACCATTATGCTGGCTATGAGCAGGTACCAATGAAGACCTCCTGACCAACTGC
-----+-----+-----+-----+-----+-----+-----+
361 AGGAACCTTGGTAATACGACCGATACTCGTCCAGTGGTTACTTCTGGAGGACTGGTTGACG 420

ACGCTATTGCTGTGCCGCCGGCTGCTGTACCCCATGAACCTGCTGTCTCTGCACACGGCT
-----+-----+-----+-----+-----+-----+-----+
421 TGCGATAACGACACGGCGGCCGACGACAGTGGGTACTTGGACGACAGAGACGTGTGCCGA 480

TCGGGGCTGCGCCTCTTCTCTGTGCTCAGCCTGGCCTGGGGCTTCATTGCTGATGTGGAC
-----+-----+-----+-----+-----+-----+-----+
481 AGCCCCGACGCGGAGAAGAGACACGAGTCGGACCGGACCCCGAAGTAACGACTACACCTG 540

CTAGAGAGTGAGAAGTATCGGCGTCTGGGGGAGATGCGCTTCACTCTGGGCACCTTCCTG
-----+-----+-----+-----+-----+-----+-----+
541 GATCTCTCACTCTTCATAGCCGACAGCCCCCTCTACGCGAAGTGAGACCCGTGGAAGGAC 600

CGTCTGGCAGCCCTGCGCACCTACCGCGGCCGACTGGCCCTACCTCCCTGTAGGAAGAGTG
-----+-----+-----+-----+-----+-----+-----+
601 GCAGACCGTTCGGGACGCGTGGATGGCGCCGGCTGACCGGATGGAGGGACATCCTTCTCAC 660

GGTTCCAAGACACCTGCCTCCCCCGTTGTGGTCCAGCAGGGCCCGGTAGATGCACACCTT
-----+-----+-----+-----+-----+-----+-----+
661 CCAAGGTTCTGTGGACGGAGGGGGCAACACCAGGTTCGTCCCGGGCCATCTACGTGTGGAA 720

GTGCCACTGGAGGAGCCAGTGCCCTCTCACTGGACAGTGGTGCCCGACGAGGACTTTGTG
-----+-----+-----+-----+-----+-----+-----+
721 CACGGTGACCTCCTCGGTACGGGAGAGTGACCTGTACCACGGGCTGCTCCTGAAACAC 780

2/22

Figure 1 cont'd

CTAGTCCTGGCACTGCTGCACTCGCACCTGGGCAGTGAGATGTTTGCTGCACCCATGGGC
-----+-----+-----+-----+-----+-----+-----+
781 GATCAGGACCGTGACGACGTGAGCGTGAGCCCGTCACTCTACAAACGACGTGGGTACCCG 840
CGCTGTGCAGCTGGCGTCATGCATCTGTTCTACGTGCGGGCGGGAGTGCTCTCGTGCCATG
-----+-----+-----+-----+-----+-----+-----+
841 GCGACACGTGACCCGAGTACGTAGACAAGATGCACGCCCGCCCTCACAGAGCACGGTAC 900
CTGCTGCGCCTCTTCCTGGCCATGGAGAAGGGCAGGCATATGGAGTATGAATGCCCCCTAC
-----+-----+-----+-----+-----+-----+-----+
901 GACGACGCGGAGAAGGACCGGTACCTCTTCCCGTCCGTATACCTCATACTTACGGGGATG 960
TTGGTATATGTGCCCCGTGGTTCGCTTCCGCTTGGAGCCCAAGGATGGGAAAGGTGTGTTT
-----+-----+-----+-----+-----+-----+-----+
961 AACCATATACAGGGCACCAGCGGAAGGCGAACCTCGGGTTCCTACCCTTTCCACACAAA 1020
GCAGTGGATGGGGAATTGATGGTTAGGCGAGCCGTGCAGGGCCAGGTGCACCCAAACTAC
-----+-----+-----+-----+-----+-----+-----+
1021 CGTCACCTACCCCTTAACCTACCAATCcgCTCGGCACGTCCCGGTCCACGTGGGTTTGATG 1080
TTCTGGATGGTCAGCGGTTGCGTGGAGCCCCCGCCAGCTGGAAGCCCCAGCAGATGCCA
-----+-----+-----+-----+-----+-----+-----+
1081 AAGACCTACCAGTCGCCAACGCACCTCGGGGGCGGGTCGACCTTCGGGGTTCGTCTACGGT 1140
CCGCCAGAAGAGCCCTTATGACCCCTGGGCGCGCTGTGCCTTAGTGTCTACTTGCAGGA
-----+-----+-----+-----+-----+-----+-----+
1141 GGCGGTCTTCTCGGGAATACTGGGGACCCGCGCGACACGGAATCACAGATGAACGTCCT 1200
CCCTTCCTCCTTCCCTAGGGCTGCAGGGCCTGTCCACAGCTCCTGTGGGGGTGGAGGAGA
-----+-----+-----+-----+-----+-----+-----+
1201 GGGAAAGGAGGAAGGGATCCCGACGTCCCGGACAGGTGTCGAGGACACCCCCACCTCCTCT 1260
CTCCTCTGGAGAAGGGTGAGAAGGTGGAGGCTATGCTTTGGGGGGACAGGCCAGAATGAA
-----+-----+-----+-----+-----+-----+-----+
1261 GAGGAGACCTCTTCCCACTCTTCCACCTCCGATACGAAACCCCCCTGTCCGGTCTTACTT 1320
GTCCTGGGTGAGGAGCCCAGCTGGCTGGGCCCAGCTGCCTATGTAAGGCCCTTCTAGTTTG
-----+-----+-----+-----+-----+-----+-----+
1321 CAGGACCCAGTCTCGGGTCGACCGACCCGGGTGACGGATACATTCCGGAAGATCAAAC 1380
TTCTGAGACCCCCACCCACGAACCAAATCCAAATAAAGTGACATTCCCAAAAAAAAAA
-----+-----+-----+-----+-----+-----+-----+
1381 AAGACTCTGGGGGTGGGGTGCTTGGTTTAGGTTTATTTCACTGTAAGGGTTTTTTTTTTT 1440
AAAAAAA
1441 ----- 1447
TTTTTTT

3/22

Figure 2. Coding region of human PSKA cDNA sequence.

ATGGATCCAGCGGGCGGCCCCCGGGGCGTGCTCCCGCGGCCCTGCCGCGTGCTGGTGCTG
7 -----+-----+-----+-----+-----+-----+-----+-----+----- 66
TACCTAGGTGCGCCGCGGGGGCCCCGACGAGGGCGCCGGGACGGCGCACGACCACGAC
CTGAACCCGCGCGGGCGGCAAGGGCAAGGCCTTGCAGCTCTTCCGGAGTCACGTGCAGCCC
67 -----+-----+-----+-----+-----+-----+-----+-----+----- 126
GACTTGGGCGCGCCGCCGTTCCCGTTCCGGAACGTGAGAAAGGCCTCAGTGCACGTGCGG
CTTTTGGCTGAGGCTGAAATCTCCTTACGCTGATGCTCACTGAGCGGCGGAACCACGCG
127 -----+-----+-----+-----+-----+-----+-----+-----+----- 186
GAAAACCGACTCCGACTTTAGAGGAAGTGCGACTACGAGTGACTCGCCGCCTTGGTGCGC
CGGGAGCTGGTGCGGTGCGAGGAGCTGGGCGCGTGGGACGCTCTGGTGCTCATGTCTGGA
187 -----+-----+-----+-----+-----+-----+-----+-----+----- 246
GCCCTCGACCACGCCAGCCTCCTCGACCCGGCGACCCTGCGAGACCACAGTACAGACCT
GACGGGCTGATGCACGAGGTGGTGAACGGGCTCATGGAGCGGCCTGACTGGGAGACCGCC
247 -----+-----+-----+-----+-----+-----+-----+-----+----- 306
CTGCCCCGACTACGTGCTCCACCACTTGCCCCGAGTACCTCGCCGGACTGACCCTCTGGCGG
ATCCAGAAaCCCCCTGTGTATCCTCCCAGCAGGCTCTGGCAACGCGCTGGCAGCTTCCTTG
307 -----+-----+-----+-----+-----+-----+-----+-----+----- 366
TAGGTCTTtGGGGACACATAGGAGGGTCGTCCGAGACCGTTGCGCGACCGTCGAAGGAAC
AACCATTATGCTGGCTATGAGCAGGTACCAATGAAGACCTCCTGACCAACTGCACGCTA
367 -----+-----+-----+-----+-----+-----+-----+-----+----- 426
TTGGTAATACGACCGATACTCGTCCAGTGTTACTTCTGGAGGACTGGTTGACGTGCGAT
TTGCTGTGCCGCGGGCTGCTGTCACCCATGAACCTGCTGTCTCTGCACACGGCTTCGGGG
427 -----+-----+-----+-----+-----+-----+-----+-----+----- 486
AACGACACGGCGGCGGACGACAGTGGGTACTTGGACGACAGAGACGTGTGCCGAAGCCCC
CTGCGCCTCTTCTCTGTGCTCAGCCTGGCCTGGGGCTTCATTGCTGATGTGGACCTAGAG
487 -----+-----+-----+-----+-----+-----+-----+-----+----- 546
GACGCGGAGAAGAGACACGAGTCGGACCGGACCCCGAAGTAACGACTACACCTGGATCTC
AGTGAGAAGTATCGGCGTCTGGGGGAGATGCGCTTCACTCTGGGCACCTTCCTGCGTCTG
547 -----+-----+-----+-----+-----+-----+-----+-----+----- 606
TCACTCTTCATAGCCGCGAGACCCCTCTACGCGAAGTGAGACCCGTGGAAGGACGCAGAC
GCAGCCCTGCGCACCTACCGCGGCCGACTGGCCTACCTCCCTGTAGGAAGAGTGGGTTC
607 -----+-----+-----+-----+-----+-----+-----+-----+----- 666
CGTGGGACGCGTGGATGGCGCCGGCTGACCGGATGGAGGGACATCCTTCTACCCAAGG
AAGACACCTGCCTCCCCGTTGTGGTCCAGCAGGGCCCCGGTAGATGCACACCTTGTGCCA
667 -----+-----+-----+-----+-----+-----+-----+-----+----- 726
TTCTGTGGACGGAGGGGGCAACACCAGGTGCTCCCGGGCCATCTACGTGTGGAACACGGT
CTGGAGGAGCCAGTGCCCTCTCACTGGACAGTGGTGCCCGACGAGGACTTTGTGCTAGTC
727 -----+-----+-----+-----+-----+-----+-----+-----+----- 786
GACCTCCTCGGTACGGGAGAGTGACCTGTCACCACGGGCTGCTCCTGAAACACGATCAG
CTGGCACTGCTGCACTCGCACCTGGGCAGTGAGATGTTTGCTGCACCCATGGGCCGCTGT
787 -----+-----+-----+-----+-----+-----+-----+-----+----- 846
GACCGTGACGACGTGAGCGTGGACCCGTCACCTCTACAAACGACGTGGGTACCCGGCGACA
GCAGCTGGCGTCAATGCATCTGTTCTACGTGCGGGCGGGAGTGTCTCGTGCCATGCTGCTG

SUBSTITUTE SHEET (RULE 26)

4/22

Figure 2 cont'd

847 -----+-----+-----+-----+-----+-----+-----+-----+-----+----- 906
CGTCGACCGCAGTACGTAGACAAGATGCACGCCCGCCCTCACAGAGCACGGTACGACGAC
CGCCTCTTCCTGGCCATGGAGAAGGGCAGGCATATGGAGTATGAATGCCCCCTACTTGGTA
907 -----+-----+-----+-----+-----+-----+-----+-----+-----+----- 966
GCGGAGAAGGACCGGTACCTCTTCCCGTCCGTATACCTCATACTTACGGGGATGAACCAT
TATGTGCCCCGTGGTCGCCTTCCGCTTGGAGCCCAAGGATGGGAAAGGTGTGTTTGCAGTG
967 -----+-----+-----+-----+-----+-----+-----+-----+-----+----- 1026
ATACACGGGCACCAGCGGAAGGCGAACCTCGGGTTCCTACCCTTTCCACACAAACGTCAC
GATGGGGAATTGATGGTTAGGCGAGCCGTGCAGGGCCAGGTGCACCCAACTACTTCTGG
1027 -----+-----+-----+-----+-----+-----+-----+-----+-----+----- 1086
CTACCCCTTAATACTACCAATCAGCTCGGCACGTCCCGGTCCACGTGGGTTTGATGAAGACC
ATGGTCAGCGGTTGCGTGGAGCCCCCGCCAGCTGGAAGCCCCAGCAGATGCCACCGCCA
1087 -----+-----+-----+-----+-----+-----+-----+-----+-----+----- 1146
TACCAGTCGCCAACGCACCTCGGGGGCGGGTCGACCTTCGGGGTCGTCTACGGTGGCGGT
GAAGAGCCCTTATGA
1147 -----+-----+-----+-----+-----+-----+-----+-----+-----+----- 1161
CTTCTCGGGAATACT

5/22

Figure 3. Predicted amino acid sequence of human PSKA protein.

1	MDPAGGPRGVLPRPCRVLVLLNPRGGK GKALQLFRSHVQPLLAEAEISFTLMLTERRNHA	60
61	RELVRSEELGRWDALVVM SGDGLMHEVVNGLMERPDWETAIQKPLCILPAGSGNALAASL	120
121	NHYAGYEQVTNEDLLTNCTLLL CRLLSPMNL LSLHTASGLRLFSVLSLAWGFIADV DLE	180
181	SEKYRRLGEMRFTLGTFLRLAALRTYRGRLAYLPVGRVGSKTPASPVVVQQGPVDAHLVP	240
241	LEEPVPSHWTVPDEDFVLVLALLHSHLGSEMFAAPMGRCAAGVMHLFYVRAGVSRAMLL	300
301	RLFLAMEKGRHMEYECPYLVYVPVVAFRLEPKDGKGVFAVDGELMVRRAVQGQVHPNYFW	360
361	MVSGCVEPPPSWK PQQMPPPEEPL*	385

6/22

Figure 4. Sequence of full-length cDNA encoding human PSKB.

AGCCGCGAGCTGGACCAGCCGTGCAAATCTCTAGAAGATGACGGTGTTCCTTTAAACGCT
1 -----+-----+-----+-----+-----+-----+-----+ 60
TCGCGCGCTCGACCTGGTCGGCACGTTTAGAGATCTTCTACTGCCACAAGAAATTTTGCGA
TCGAAATCACTGGAAGAAAACACTACAGCTGGGCTCTGCCTGCTGACCTGGGGAGGCCATTG
61 -----+-----+-----+-----+-----+-----+-----+ 120
AGCTTTAGTGACCTTCTTTTGATGTGACCCGAGACGGACGACTGGACCCCTCCGGTAAC
GCTCTATGGAACACTGTGATAACCTCCTAAGGAGAGCAGCCTGTCAAGAAGCTCAGGT
121 -----+-----+-----+-----+-----+-----+-----+ 180
CGAGATACCTTTTGTGACACTATTGGAGGATTCTCTCGTCGGACAGTTCTTCGAGTCCA
GTTTGGCAATCAACTCATTCTCCCAATGCACAAGTGAAGAAGGCCACTGTTTTTCTCAA
181 -----+-----+-----+-----+-----+-----+-----+ 240
CAAACCGTTAGTTGAGTAAGGAGGGTTACGTGTTCACTTCTTCCGGTGACAAAAGAGTT
TCCTGCAGCTTGCAAAGGAAAAGCCAGGACTCTATTTGAAAAAATGCTGCCCCGATTTT
241 -----+-----+-----+-----+-----+-----+-----+ 300
AGGACGTCGAACGTTTCCTTTTCGGTCCTGAGATAAACTTTTTTTACGACGGGGCTAAAA
ACATTTATCTGGCATGGATGTGACTATTGTTAAGACAGATTATGAGGGACAAGCCAAGAA
301 -----+-----+-----+-----+-----+-----+-----+ 360
TGTAATAGACCGTACCTACACTGATAACAATTCTGTCTAATACTCCCTGTTCCGGTTCTT
ACTCCTGGAAC TGATGGAAAACACGGATGTGATCATTGTTGCAGGAGGAGATGGGACACT
361 -----+-----+-----+-----+-----+-----+-----+ 420
TGAGGACCTTGACTACCTTTTGTGCCTACACTAGTAACAACGTCTCTCTACCTGTGA
GCAGGAGGTTGTTACTGGTGTTCCTTCGACGAACAGATGAGGCTACCTTCAGTAAGATTCC
421 -----+-----+-----+-----+-----+-----+-----+ 480
CGTCCTCCAACAATGACCACAAGAAGCTGCTTGTCTACTCCGATGGAAGTCATTCTAAGG
CATTGGATTTATCCCACTGGGAGAGACCAGTAGTTTGTAGTCATACCCTCTTTGCCGAAAG
481 -----+-----+-----+-----+-----+-----+-----+ 540
GTAACCTAAATAGGGTGACCTCTCTGGTCATCAAACTCAGTATGGGAGAAACGGCTTTC
TGGAACAAAGTECAACATATTACTGATGCCACACTTGCCATTGTGAAAGGAGAGACAGT
541 -----+-----+-----+-----+-----+-----+-----+ 600
ACCTTTGTTTCAGGTTGTATAATGACTACGGTGTGAACGGTAACACTTTCCTCTCTGTCA
TCCACTTGATTTCTTGCAGATCAAGGGTGAAAAGGAACAGCCTGTATTTGCAATGACCGG
601 -----+-----+-----+-----+-----+-----+-----+ 660
AGGTGAAC TAAAGAACGTCTAGTTCCCACTTTTCCTTGTCTCGGACATAAACGTTACTGGCC
CCTTCGATGGGGATCTTTCAGAGATGCTGGCGTCAAAGTTAGCAAGTACTGGTATCTTGG
661 -----+-----+-----+-----+-----+-----+-----+ 720
GGAAGCTACCCCTAGAAAGTCTCTACGACCGCAGTTTCAATCGTTCATGACCATAGAACC
GCCTCTAAAAATCAAAGCAGCCCACTTTTTTTCAGCACTCTTAAGGAGTGGCCTCAGACTCA
721 -----+-----+-----+-----+-----+-----+-----+ 780
CGGAGATTTTTAGTTTCGTCTGGGTGAAAAAGTCGTGAGAATTCCTCACCAGGAGTCTGAGT
TCAAGCCTCTATCTCATAACCGGGACCTACAGAGAGACCTCCCAATGAACCAGAGGAGAC
781 -----+-----+-----+-----+-----+-----+-----+ 840
AGTTCGGAGATAGAGTATGTGCCCTGGATGTCTCTCTGGAGGGTTACTTGGTCTCCTCTG
CCCTGTACAAAGGCCTTCTTTGTACAGGAGAATATTACGAAGGCTTGCCTCTACTGGGC

SUBSTITUTE SHEET (RULE 26)

Figure 4 cont'd

7/22

841 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 900
GGGACATGTTTCCGGAAGAAACATGTCCTCTTATAATGCTTCCGAACGCAGGATGACCCG
ACAACCACAGGATGCCCTTTCCCAAGAGGTGAGCCCGGAGGTCTGGAAAGATGTGCAGCT
901 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 960
TGTTGGTGTCCTACGGGAAAGGGTTCTCCACTCGGGCCTCCAGACCTTTCTACACGTCGA
GTCCACCATTTGAACTGTCCATCACAACACGGAATAATCAGCTTGACCCGACAAGCAAAGA
961 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1020
CAGGTGGTAACCTTGACAGGTAGTGTGTGCCTTATTAGTCGAACTGGGCTGTTCTGTTTCT
AGATTTTCTGAATATCTGCATTGAACCTGACACCATCAGCAAAGGAGACTTTATAACTAT
1021 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1080
TCTAAAAGACTTATAGACGTAACCTGGACTGTGGTAGTCGTTTCCTCTGAAATATTGATA
AGGAAGTCGAAAGGTGAGAAACCCCAAGCTGCACGTGGAGGGCACGGAGTGTCTCCAAGC
1081 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1140
TCCTTCAGCTTTCCACTCTTTGGGGTTCGACGTGCACCTCCCGTGCCTCACAGAGGTTCG
CAGCCAGTGCACCTTTGCTTATCCCGGAGGGAGCAGGGGGCTCTTTTAGCATTGACAGTGA
1141 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1200
GTCGGTCACGTGAAACGAATAGGGCCTCCCTCGTCCCCGAGAAAATCGTAACTGTCACT
GGAGTATGAAGCGATGCCTGTGGAGGTGAACTGCTCCCCAGGAAGCTGCAGTTCTTCTG
1201 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1260
CCTCATACTTCGCTACGGACACCTCCACTTTGACGAGGGGTCTTCGACGTCAAGAAGAC
TGATCCTAGGAAGAGAGAACAGATGCTCACAAGCCCCACCCAGTGAGCAGCAGAAGACAA
1261 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1320
ACTAGGATCCTTCTCTCTTGTCTACGAGTGTTCGGGGTGGGTCACTCGTCGTCTTCTGTT
GCACTCTGAGACCACACTTTTAGGCCACCGGTGGGACCAAAGGGAACAGGTGCCTCAGCC
1321 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1380
CGTGAGACTCTGGTGTGAAATCCGGTGGCCACCCTGGTTTTCCCTTGTCCACGGAGTCGG
ATCCCAACAGTGTCTCAGAGGGTCCCCAGGGCATTTTCATGGCAAGTACCCCTCTGCCC
1381 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1440
TAGGGTTGTACAGCAGTCTCCCAGGGGTCCCGTAAAAGTACCGTTTCATGGGGAGACGGG
CCACTCCAGCAGTGCTTCCCAAAGTGTGCTCTGTACCTGCTTTGCAATCGGCTTCCATT
1441 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1500
GGTGAGGTCTGCACGAAGGGTTTACACGAGACAGTGGACGAAACGTTAGCCGAAGGTAA
AGCGCATGTTTTATTTTGGTGTGACGGTTGGCCCTCCTAAACACGGACTTTCTCTCAGGCT
1501 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1560
TCGCGTACAAAATAAAACCACACTGCCAACCGGGAGGATTTGTGCCTGAAAGGAGTCCGA
GGTTCAAGACGGAAAAGGACTTTCTTCTGTTTTCTTCCAAAGTGCAACCACAGTGGAGAG
1561 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1620
CCAAGTTCTGCCTTTTCTGAAAGAAGACAAAAGAAGGTTTCACGTTGGTGTACCTCTC
CCCACGGTGGGCTTAGCCTGCCTAGGCCCTTCCATTTCTCTTCTTTGACCGTGCTAGGAA
1621 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1680
GGGTGCCACCCGAATCGGACGGATCCGGGAAGGTAAAGAGAAGAACTGGCAGGATCCTT
TTCCAGGAAAGTGCAATTCCTGCCCTGGTGACCTTTTCTATGTCTAGGCTCCTCCACAGG
1681 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 1740
AAGGTCCTTTACGTAAGGACGGGACCACTGGAAAAGGATACAGATCCGAGGAGGTGTCC
TGCTGCTATTTTGTGAGCTCCGGCTCCTGTTTAGCTTTTATTTTCAGTTCTAACCTCAGTC

SUBSTITUTE SHEET (RULE 26)

Figure 4 cont'd

8/22

1741 -----+-----+-----+-----+-----+-----+-----+ 1800
ACGACGATAAAACACTCGAGGCCGAGGACAAATCGAAAATAAAGTCAAGATTGGAGTCAG
CAGAAACATATGTGAGGTTGTTTCCCTCTTCAGCCACGGCTACAATACCGGAAAATGCTA
1801 -----+-----+-----+-----+-----+-----+-----+ 1860
GTCTTTGTATACACTCCAACAAAGGGAGAAGTCGGTGCCGATGTTATGGCCTTTTACGAT
GTTTTTATTTATTTTAAAGTAGTGCTTCCTAAATGGTTTGCATGAGAGCCACCTGGGG
1861 -----+-----+-----+-----+-----+-----+-----+ 1920
CAAAAATAAATAAAAAAATTCATCACGAAGGATTTACCAAACGTACTCTCGGTGGACCCC
TACATGTTGAAAACCTTATTTGGGGTCTACCCCCAAACCTAATAACCCAAATTTGGGGATGG
1921 -----+-----+-----+-----+-----+-----+-----+ 1980
ATGTACAACCTTTTGAATAAACCCAGATGGGGTTTGGATTATTGGGTTTAAACCCCTACC
GGCCAGGAATATGCATTTTTTAAAAAGTCATCTGCCCTTCCAGGTGATTCTGTAAGTTG
1981 -----+-----+-----+-----+-----+-----+-----+ 2040
CCGGGTCTTTATACGTAAAAATTTTTTCAGTAGACGGGAAGGGTCCACTAAGACATTCAAC
TCCCTCAACTGTACTTGGAGAAATCGTGTTTTTAAAGCAGTAGTCCACAAAGTATTCTGCT
2041 -----+-----+-----+-----+-----+-----+-----+ 2100
AGGGAGTTGACATGAACCTCTTTAGCACAAAATTTTCGTCATCAGGTGTTTCATAAGACGA
CATGTGCCCCCAAAGTATTTTGAAAAATCATGTATACCCCTACCCATCTAAGTTGATAT
2101 -----+-----+-----+-----+-----+-----+-----+ 2160
GTACACGGGGGTTTTTCATAAACTTTTTAGTACATATGGGAGTGGGTAGATTCAACTATA
CTAAAATTTTATCTAAGTTGGTATCTAAAATTTTTTCATGGGAAGTTAAATAGTTGACAAA
2161 -----+-----+-----+-----+-----+-----+-----+ 2220
GATTTTAAAATAGATTCAACCATAGATTTTAAAAAGTACCCTTCAATTTATCAACTGTTT
GTATGTATTTGCTGGTGTCTGTAAATATTGGTATTTTAAAATAAAAACTGTTACATCAC
2221 -----+-----+-----+-----+-----+-----+-----+ 2280
CATACATAAACGACCACAGCACATTTATAACCATAAAATTTTATTTTTTGACAATGTAGTG
TAAWWAAAAAAAAAAAAAAAAAAAAA
2281 -----+-----+-----+-----+-----+-----+-----+ 2306
ATTWWTTTTTTTTTTTTTTTTTTTTT

9/22

Figure 5. Coding region of human PSKB cDNA sequence.

```

38  ATGACGGTGTCTTTAAACGCTTCGAAATCACTGGAAGAAACTACAGCTGGGCTCTGC
   +-----+-----+-----+-----+-----+-----+-----+
97  TACTGCCACAAGAAATTTGCGAAGCTTTAGTGACCTTCTTTTGATGTCGACCCGAGACG
   CTGCTGACCTGGGGAGGCCATTGGCTCTATGGAACAACTGTGATAACCTCCTAAGGAGA
158  +-----+-----+-----+-----+-----+-----+-----+
   GACGACTGGACCCCTCCGGTAACCGAGATACCTTTTGTGACACTATTGGAGGATTCTCT
   GCAGCCTGTCAAGAAGCTCAGGTGTTTGGCAATCAACTCATTCTCCCAATGCACAAGTG
217  +-----+-----+-----+-----+-----+-----+-----+
   CGTCGGACAGTTCTTCGAGTCCACAAACCGTTAGTTGAGTAAGGAGGGTTACGTGTTTAC
   AAGAAGGCCACTGTTTTTCTCAATCCTGCAGCTTGCAAAGGAAAAGCCAGGACTCTATTT
277  +-----+-----+-----+-----+-----+-----+-----+
   TTCTTCCGGTGACAAAAGAGTTAGGACGTCGAACGTTTCCTTTTCGGTCCTGAGATAAA
   GAAAAAATGCTGCCCCGATTTTACATTTATCTGGCATGGATGTGACTATTGTTAAGACA
337  +-----+-----+-----+-----+-----+-----+-----+
   CTTTTTTTACGACGGGGCTAAAATGTAAATAGACCGTACCTACACTGATAACAATTCTGT
   GATTATGAGGGACAAGCCAAGAACTCCTGGAAGTATGGAAAACACGGATGTGATCATT
397  +-----+-----+-----+-----+-----+-----+-----+
   CTAATACTCCCTGTTTCGGTCTTTGAGGACCTTGACTACCTTTTGTGCCTACACTAGTAA
   GTTGCAGGAGGAGATGGGACACTGCAGGAGGTTGTTACTGGTGTCTTCGACGAACAGAT
457  +-----+-----+-----+-----+-----+-----+-----+
   CAACGTCCTCCTCTACCCTGTGACGTCCTCCAACAATGACCACAAGAAGCTGCTTGTCTA
   GAGGCTACCTTCAGTAAGATTCCCATTTGATTATCCCACTGGGAGAGACCAGTAGTTTG
517  +-----+-----+-----+-----+-----+-----+-----+
   CTCCGATGGAAGTCATTCTAAGGGTAACCTAAATAGGGTGACCCTCTCTGGTCATCAAAC
   AGTCATACCCTCTTTGCCGAAAGTGGAACAAAGTCCAACATATTACTGATGCCACACTT
577  +-----+-----+-----+-----+-----+-----+-----+
   TCAGTATGGGAGAAACGGCTTTACCTTTGTTTCAGGTTGTATAATGACTACGGTGTGAA
   GCCATTGTGAAAGGAGAGACAGTTCACCTTGATTTCTTGCAGATCAAGGGTGAAAAGGAA
637  +-----+-----+-----+-----+-----+-----+-----+
   CGGTAACACTTTCCTCTCTGTCAAGGTGAACATAAGAACGTCTAGTTCCCACTTTTCCTT
   CAGCCTGTATTTGCAATGACCGGCCTTCGATGGGGATCTTTCAGAGATGCTGGCGTCAAA
697  +-----+-----+-----+-----+-----+-----+-----+
   GTCGGACATAAACGTTACTGGCCGGAAGCTACCCCTAGAAAGTCTCTACGACCGCAGTTT
   GTTAGCAAGTACTGGTATCTTGGGCCTCTAAAAATCAAAGCAGCCCACTTTTTTCAGCACT
757  +-----+-----+-----+-----+-----+-----+-----+
   CAATCGTTCATGACCATAGAACCCGGAGATTTTGTAGTTTCGTCGGGTGAAAAGTCGTGA
   CTTAAGGAGTGGCCTCAGACTCATCAAGCCTCTATCTCATACACGGGACCTACAGAGAGA
817  +-----+-----+-----+-----+-----+-----+-----+
   GAATTCCTCACCGGAGTCTGAGTAGTTCGGAGATAGAGTATGTGCCCTGGATGTCTCTCT
   CCTCCCAATGAACCAGAGGAGACCCCTGTACAAAGGCCTTCTTTGTACAGGAGAATATTA
877  +-----+-----+-----+-----+-----+-----+-----+
   GGAGGGTTACTTGGTCTCCTCTGGGGACATGTTTCCGGAAGAAACATGTCTCTTATAAT
   CGAAGGCTTGCGTCCTACTGGGCACAACCACAGGATGCCCTTTCCCAAGAGGTGAGCCCG
937  +-----+-----+-----+-----+-----+-----+-----+

```

Figure 5 cont'd

10/22

GCTTCCGAACGCAGGATGACCCGTGTTGGTGTCTACGGGAAAGGGTTCTCCACTCGGGC
GAGGTCTGGAAAGATGTGCAGCTGTCCACCATTGAACTGTCCATCACAACACGGAATAAT
938 -----+-----+-----+-----+-----+-----+-----+----- 997
CTCCAGACCTTTCTACACGTCGACAGGTGGTAACTTGACAGGTAGTGTGTGCCTTATTA
CAGCTTGACCCGACAAGCAAAGAAGATTTTCTGAATATCTGCATTGAACCTGACACCATC
998 -----+-----+-----+-----+-----+-----+-----+----- 1057
GTCGAACTGGGCTGTTTCGTTTCTTCTAAAAGACTTATAGACGTAACCTTGGACTGTGGTAG
AGCAAAGGAGACTTTATAACTATAGGAAGTCGAAAGGTGAGAAACCCCAAGCTGCACGTG
1058 -----+-----+-----+-----+-----+-----+-----+----- 1117
TCGTTTCCTCTGAAATATTGATATCCTTCAGCTTTCCACTCTTTGGGGTTTCGACGTGCAC
GAGGGCACGGAGTGTCTCCAAGCCAGCCAGTGCACCTTTGCTTATCCCGGAGGGAGCAGGG
1118 -----+-----+-----+-----+-----+-----+-----+----- 1177
CTCCCGTGCCTCACAGAGGTTCCGGTCGGTCACGTGAAACGAATAGGGCCTCCCTCGTCCC
GGCTCTTTTAGCATTGACAGTGAGGAGTATGAAGCGATGCCTGTGGAGGTGAAACTGCTC
1178 -----+-----+-----+-----+-----+-----+-----+----- 1237
CCGAGAAAATCGTAACTGTCACTCCTCATACTTCGCTACGGACACCTCCACTTTGACGAG
CCCAGGAAGCTGCAGTTCTTCTGTGATCCTAGGAAGAGAGAACAGATGCTCACAAGCCCC
1238 -----+-----+-----+-----+-----+-----+-----+----- 1297
GGGTCCTTCGACGTCAAGAAGACACTAGGATCCTTCTCTCTTGTCTACGAGTGTTTCGGGG
ACCCAGTGA
1298 -----+----- 1306
TGGGTCACT

11/22

Figure 6. Predicted polypeptide sequence of human PSKB protein.

```
MTVFFKTLRNHWKKT TAGLCLLTWGGHWLYGKHCDNLLRRAACQEAQVFGNQLIPPNAQV
1  -----+-----+-----+-----+-----+-----+-----+ 60

KKATVFLNPAACKGKARTLFEKNAAPILHLSGMDVTIVKTDYEGQAKKLELMENTDVII
61  -----+-----+-----+-----+-----+-----+-----+ 120

VAGGDGTLQEVVTGVLRRRTDEATFSKIPIGFIPLGETSSLSHTLFAESGNKVQHITDATL
121 -----+-----+-----+-----+-----+-----+-----+ 180

AIVKGETVPLDFLQIKGEKEQPVFAMTGLRWGSFRDAGVKVSKYWYLGPLKIKAAHFFST
181 -----+-----+-----+-----+-----+-----+-----+ 240

LKEWPQTHQASISYTGPTERPPNEPEETPVQRPSLYRRILRRLASYWAQPQDALSQEVSP
241 -----+-----+-----+-----+-----+-----+-----+ 300

EVWKDVQLSTIELSITTRNNQLDPTSKEDFLNICIEPDTISKGDFITIGSRKVRNPKLHV
301 -----+-----+-----+-----+-----+-----+-----+ 360

EGTECLQASQCTLLIPEGAGGSFSIDSEEYEAMPVEVKLLPRKLQFFCDPRKREQMLTSP
361 -----+-----+-----+-----+-----+-----+-----+ 420

TQ*
421--- 423
```

12/22

Figure 7. Full-length human PSKC cDNA sequence.

ATCTGAGATCATCGCCGTTGAGGAAACAGACGTTACGGGAAACATCAAGGCAGTGGA
1 -----+-----+-----+-----+-----+-----+-----+ 60
TAGACTCTAGTAGCGGCAACTCCTTTGTCTGCAAGTGCCCTTTGTAGTTCCGTCACCTTT
ATGGCAGAAAATGGAAAAGCCTTACGCTTTTACAGTTCACTGTGTAAAGAGAGCACGACG
61 -----+-----+-----+-----+-----+-----+-----+ 120
TACCGTCTTTTACCTTTTCGGAATGCGAAAATGTCAAGTGACACATTTCTCTCGTGCTGC
GCACCGCTGGAAGTGGGCGCAGGTGACTTTCTGGTGTCCAGAGGAGCAGCTGTGTCACTT
121 -----+-----+-----+-----+-----+-----+-----+ 180
CGTGGCGACCTTCACCCGCGTCCACTGAAAGACCACAGGTCTCCTCGTCGACACAGTGAA
GTGGCTGCAGACCCTGCGGGAGATGCTGGAGAAGCTGACGTCCAGACCAAAGCATTACT
181 -----+-----+-----+-----+-----+-----+-----+ 240
CACCGACGTCTGGGACGCCCTCTACGACCTCTTCGACTGCAGGTCTGGTTTCGTAAATGA
GGTATTTATCAACCCGTTTGGAGGAAAAGGACAAGGCAAGCGGATATATGAAAGAAAAGT
241 -----+-----+-----+-----+-----+-----+-----+ 300
CCATAAATAGTTGGGCAAACCTCCTTTTCTGTTCCGTTTCGCTATATACTTTCTTTTCA
GGCACCCTGTTCACCTTAGCCTCCATCACCCTGACATCATCGTTACTGAACATGCTAA
301 -----+-----+-----+-----+-----+-----+-----+ 360
CCGTGGTGACAAGTGGGAATCGGAGGTAGTGGTGAAGTGTAGTAGCAATGACTTGTACGATT
TCAGGCCAAGGAGACTCTGTATGAGATTAACATAGACAAATACGACGGCATCGTCTGTGT
361 -----+-----+-----+-----+-----+-----+-----+ 420
AGTCCGGTTTCTCTGAGACATACTCTAATTGTATCTGTTTATGCTGCCGTAGCAGACACA
CGGCGGAGATGGTATGTTTACGCGAGGTGCTGCACGGTCTGATTGGGAGGACGCAGAGGAG
421 -----+-----+-----+-----+-----+-----+-----+ 480
GCCGCCTCTACCATACAAGTCGCTCCACGACGTGCCAGACTAACCCTCCTGCGTCTCCTC
CGCCGGGGTTCGACCAGAACACCCCCGGGCTGTGCTGGTCCCCAGTAGCCTCCGGATTGG
481 -----+-----+-----+-----+-----+-----+-----+ 540
GCGGCCCCAGCTGGTCTTGGTGGGGGCCGACACGACCAGGGGTATCGGAGGCCTAACC
AATCATTTCCCGCAGGGTCAACGGACTGCGTGTGTTACTCCACCGTGGGCACCAGCGACGC
541 -----+-----+-----+-----+-----+-----+-----+ 600
TTAGTAAGGGCGTCCAGTTGCCTGACGCACACAATGAGGTGGCACCCGTGGTCTGCTGCG
AGAAACCTCGGCGCTGCATATCGTTGTTGGGGACTCGCTGGCCATGGATGTGTCTCAGT
601 -----+-----+-----+-----+-----+-----+-----+ 660
TCTTTGGAGCCGCGACGTATAGCAACAACCCCTGAGCGACCGGTACCTACACAGGAGTCA
CCACCACAACAGCACACTCCTTCGCTACTCCGTGTCCCTGCTGGGCTACGGCTTCTACGG
661 -----+-----+-----+-----+-----+-----+-----+ 720
GGTGGTGTGTGCTGTGAGGAAGCGATGAGGCACAGGGACGACCCGATGCCGAAGATGCC
GGACATCATCAAGGACAGTGAGAAGAAACGGTGGTTGGGTCTTGCCAGATACGACTTTTC
721 -----+-----+-----+-----+-----+-----+-----+ 780
CCTGTAGTAGTTCCTGTCACTCTTCTTTGCCACCAACCCAGAACGGTCTATGCTGAAAAG

Figure 7 cont'd

13/22

781 AGGTTTAAAGACCTTCCTCTCCCACCACTGCTATGAAGGGACAGTGTCTTCCTCCCTGC
-----+-----+-----+-----+-----+-----+-----+ 840
TCCAAATTTCTGGAAGGAGAGGGTGGTGACGATACTTCCTGTACAGGAAGGAGGGACG

841 ACAACACACGGTGGGATCTCCAAGGGATAGGAAGCCCTGCCGGGCAGGATGCTTTGTTTG
-----+-----+-----+-----+-----+-----+-----+ 900
TGTTGTGTGCCACCCTAGAGGTTCCCTATCCTTCGGGACGGCCCGTCCTACGAAACAAAC

901 CAGGCAAAGCAAGCAGCAGCTGGAGGAGGAGCAGAAGAAAGCACTGTATGGTTTGGAAGC
-----+-----+-----+-----+-----+-----+-----+ 960
GTCCGTTTCGTTTCGTCGTCGACCTCCTCCTCGTCTTCTTTCTGTGACATACCAAACCTTCG

961 TCGGGAGGACGTGGAGGAGTGGCAAGTCGTCTGTGGGAAGTTTCTGGCCATCAATGCCAC
-----+-----+-----+-----+-----+-----+-----+ 1020
ACGCCCTCTGCACCTCCTCACCCTTCAGCAGACACCCTTCAAAGACCGGTAGTTACGGTG

1021 AAACATGTCTGTGCTTGTGCGCCGAGCCCCAGGGGCCTCTCCCCGGCTGCCCACTTGGG
-----+-----+-----+-----+-----+-----+-----+ 1080
TTTGTACAGGACACGAACAGCGGCCTCGGGGTCCCCGAGAGGGGCGACGGGTGAACCC

1081 AGACGGGTCTTCTGACCTCATCCTCATCCGAAATGCTCCAGGTTCAATTTTCTGAGATT
-----+-----+-----+-----+-----+-----+-----+ 1140
TCTGCCCAGAAGACTGGAGTAGGAGTAGGCCTTTACGAGGTCCAAGTTAAAGACTCTAA

1141 TCTCATCAGGCACACCAACCAGCAGGACCAGTTTGACTTCACTTTTGTGTAAGTTTATCG
-----+-----+-----+-----+-----+-----+-----+ 1200
AGAGTAGTCCGTGTGGTTGGTCGTCTGGTCAAACCTGAAGTGAAAACAACCTTCAAATAGC

1201 CGTCAAGAAATTCAGTTTACGTGCAAGCACATGGAGGATGAGGACAGCGACCTCAAGGA
-----+-----+-----+-----+-----+-----+-----+ 1260
GCAGTTCTTTAAGGTCAAATGCAGCTTCGTGTACCTCCTACTCCTGTGCTGGAGTTCTT

1261 GGGGGGGAAGAAGCGCTTTGGGCACATTTGCAGCAGCCACCCCTCCTGCTGCTGCACCGT
-----+-----+-----+-----+-----+-----+-----+ 1320
CCCCCCTTCTTCGCGAAACCCGTGTAAACGTGCTCGGTGGGGAGGACGACGACGTGGCA

1321 CTCCAACAGCTCCTGGAAGTGCAGCGGGGAGGTCTGTCACAGCCCTGCCATCGAGGTCAG
-----+-----+-----+-----+-----+-----+-----+ 1380
GAGGTTGTGAGGACCTTGACGCTGCCCCCTCAGGACGTGTGCGGACGGTAGCTCCAGTC

1381 AGTCCACTGCCAGCTGGTTCGACTCTTTGCACGAGAATTGGAAGAGAATCCGAAGCCAGA
-----+-----+-----+-----+-----+-----+-----+ 1440
TCAGGTGACGGTCGACCAAGCTGAGAAACGTGCTCTTAACCTTCTCTTAGGCTTCGGTCT

1441 CTCACACAGCTGAGAAGCCGGCGTCTGCTCTCGAACTGGGAAAGTGTGAAACTATTTA
-----+-----+-----+-----+-----+-----+-----+ 1500
GAGTGTGTGACTCTTCGGCCGCAGGACGAGAGCTTGACCCTTTCACACTTTTGATAAAT

1501 AGATAATTATTACAGACCAATTATGTTGATATATACATTTAAATGTAGAAATTTATTTTT
-----+-----+-----+-----+-----+-----+-----+ 1560
TCTATTAATAATGTCTGGTTAATACAACTATATGTAAATTTACATCTTTAAATAAAAA

1561 GATAGTTAAATCTTGATTTTAGAAGAAAACCCCTTTGTCAACAATTTTGTGTACATATTT
-----+-----+-----+-----+-----+-----+-----+ 1620
CTATCAATTTAGAACTAAAATCTTCTTTTGGGAAAACAGTTGTAAACACATGTATAAA

Figure 7 cont'd

14/22

1621 GGCATTTTCAGTTCTGTACGCATCTGCGGGTTGCAGCCCACGCCGCTTACTCTCAGCGGA
-----+-----+-----+-----+-----+ 1680
CCGTAAAAGTCAAGACATGCGTAGACGCCAACGTCGGGTGCGGCGAATGAGAGTCGCCT

1681 TGCAGCTGCTCACTTGGGGGCACTGGCCTCTTAGGTTTAAACGATGTCAACAGTGTAGTT
-----+-----+-----+-----+-----+ 1740
ACGTCGACGAGTGAACCCCGTGACCGGAGAATCCAAAATTGCTACAGTTGTACATCAA

1741 TAGAAAATGGCCCGTTAGTGGCTCTATTGCAATAATGTTAGGGACATTATATGATTTCCA
-----+-----+-----+-----+-----+ 1800
ATCTTTTACCGGGCAATCACCGAGATAACGTTATTACAATCCCTGTAATATACTAAAGGT

1801 CGCAGGTCACACCATCTGGGCCTGAGGTAGCAGTGGGTCACTTTGATCCACTTTGCAGGA
-----+-----+-----+-----+-----+ 1860
GCGTCCAGTGTGGTAGACCCGGACTCCATCGTCACCCAGTGAACTAGGTGAAACGTCCT

1861 CTTATTCTGTAACGGTTTGTGGCCAAGTTTTGGGAAGTGGTTGATTCTCTTTGCCTTCAT
-----+-----+-----+-----+-----+ 1920
GAATAAGACATTGCCAAACACCGGTTCAAACCCCTTCACCAACTAAGAGAAACGGAAGTA

1921 TTCACCTTCCTCTTCGTTTACGGTTAGGACATCGCTGCTTGATCCTTACAATACTGTGCA
-----+-----+-----+-----+-----+ 1980
AAGTGGAAGGAGAAGCAAATGCCAATCCTGTAGCGACGAAGTAGGAATGTTATGACACGT

1981 ACTGCAATGCAACGTGGCCCTGCTTCAGGTGATCCGCGGGAGGGGCCTCCACGCCAGCAC
-----+-----+-----+-----+-----+ 2040
TGACGTTACGTTGCACCGGGACGAAGTCCACTAGGCGCCCTCCCGGAGGTGCGGTCTGTG

2041 C3GGAAAGGCTGCTGGGGCCTCCACACCTGCCTCATCACGGGGGGGAAGCTACGACAATC
-----+-----+-----+-----+-----+ 2100
GCCCTTTCCGACGACCCCGGAGGTGTGGACGGAGTAGTGCCCCCCTTCGATGCTGTTAG

2101 CGGCTGGGAACATGACCTTGGCGTCTGTTCTGGGAACACAAATRATAARCTCTGGAARCT
-----+-----+-----+-----+-----+ 2160
GCCGACCCTTGTAAGTGAACCGCAGACAAGACCCTTGTGTTTAYTATTYAGACCTTYGA

2161 GGCAGTGTGTAAAGCACTGGCAAGTTTGTACTGTTAAATGTCAAATACCAATGCTTTA
-----+-----+-----+-----+-----+ 2220
CCGTACACATTTTCGTGACCGTTCAAACAATGACAATTTTACAGTTTATGGTTACGAAAT

2221 TATCGACGCCGAAATGCTTAACACAKCCGGGCTTGGGGGCAGTCAGGAAGAAAACCTGGCC
-----+-----+-----+-----+-----+ 2280
ATAGCTGCGGCTTTACGAATTGTGTMGGCCCCGAACCCCGTCAGTCCTTCTTTTGACCGG

2281 ATCCGTGGAGGAGGGGCCGCTCCTGGACTCCCGCAGGAYTCCTCTGATGCAGGGCCTGAA
-----+-----+-----+-----+-----+ 2340
TAGGCACCTCCTCCCCGCCAGGACCTGAGGGCGTCTRAGGAGACTACGTCCCGGACTT

2341 GTCTGTACACGTGGTCCAAATTTGTCTTGTCTTTTCTTCACACTGAGTTCTCTATATTT
-----+-----+-----+-----+-----+ 2400
CAGACATGTGCACCAGGTTTAAACAGGAACAGAAAAGAAGTGTGACTCAAGAGATATAAA

2401 ATTGAACATCTTGTCTTTTAAARCCAMGAAGTARTGTAACTGCGTCTCGGATGTCTGT
-----+-----+-----+-----+-----+ 2460
TAACTTGTAGAACAGGAAAAATTYGGTKCTTCATYACAAATTGACGCAGAGCCTACAGACA

Figure 7 cont'd

15/22

2461 CTTTTGTCTCSGAARCCACRAWGGATCKCTGGTTTCCTCTCTGCAGCGCGAGGGCTCCGG
-----+-----+-----+-----+-----+-----+ 2520
GAAAACAGAGSCTTYGGTGYTWCCCTAGMGACCAAAGGAGAGACGTCGCGCTCCCCGAGGCC

2521 CGACCAGAGGATYCTYCCCGRAAGGSATTCCTGCCGCGCTCCCCCGGGCACCCCTCAATT
-----+-----+-----+-----+-----+-----+ 2580
GCTGGTCTCCTARGARGGGCYTTCCSTAAGGACGGCGCGAGGGGGCCCGTGGGGAGTTAA

2581 GTGTACTACCGTCCCTTGTTTAAKGGTTTGTATCCCTGCCCACSTAAGATAAATGTCTGT
-----+-----+-----+-----+-----+-----+ 2640
CACATGATGGCAGGGAACAAATTMCCAAACATAGGGACGGGTGSATTCTATTTACAGACA

2641 AACGGTAGTTTTGTTTGAAAATATGAGAATATGCGGCTTAAACTTTGATCTGTAAGGAGC
-----+-----+-----+-----+-----+-----+ 2700
TTGCCATCAAAACAAACTTTTATACTCTTATACGCCGAATTTGAAACTAGACATTCCTCG

2701 GGGGCCCCGTGCCCGTTTGGAGCACGCTGTAGACMCCGTTCTCATGCTGCCGGGTGGGTT
-----+-----+-----+-----+-----+-----+ 2760
CCCCGGGCACGGGCAAACCTCGTGCACATCTGKGGCAAGGAGTACGACGGGCCACCCAA

2761 TTGCAGAAGCTCCCTTAGTGATTTTATGTTTAAACAGGCAGCATCCCATTTTTCAGAATTTT
-----+-----+-----+-----+-----+-----+ 2820
AACGTCCTTCGAGGGAATCACTAAAGTACAAATTGTCCGTCGTAGGGTAAAAGTCTTAAAG

2821 CTGGCATTGATTTTATATTTTGAAGCATACAGGAACTTCTCGTTTCCCTCGTTTAGCCC
-----+-----+-----+-----+-----+-----+ 2880
GACCGTAACTAAAATATAAACTTCGTATGTCTTTGAAGAGCAAAGGGAGCAAATCGGG

2881 CCACCCAGATCCAGGTGAAAGGGCAGCTTTAATGGTGGTTTTTATGGACCACCATTATCA
-----+-----+-----+-----+-----+-----+ 2940
GGTGGGTCTAGGTCCACTTTCCCGTCGAAATTACCACCAAAAATACCTGGTGGTAATAGT

2941 GAGAGCACTGTGCAAGCCAAATGGTTCCAATAATGAATGAAAATTTCTGGGTGTAAAGAG
-----+-----+-----+-----+-----+-----+ 3000
CTCTCGTGACACGTTTCGGTTTACCAAGGTTATTACTTACTTTTAAAGACCCACATTTCTC

3001 TAAATATGCCCCTGGCTCTTTTCTACCAATGTTTGCTTCCTGGTTGGAAAGAAACCAAAG
-----+-----+-----+-----+-----+-----+ 3060
ATTTATACGGGGACCGAGAAAAGATGGTTACAAACGAAGGACCAACCTTTCTTTGGTTTC

3061 ATTTAAGACGGGCTGCTTCTTCCAGACTGGCTGTGCCCTGCCTGTGGCCCAGCAACCTG
-----+-----+-----+-----+-----+-----+ 3120
TAAATTCTGCCCGACGAAGAAGGGTCTGACCGACACGGGACGGACACCGGGTCTTGGAC

3121 TGCAGCCGGCAGTGTGCCTGGTGTCACGCCAGGAGGCTGTGGCTGCTGTGGGCCCTCTGG
-----+-----+-----+-----+-----+-----+ 3180
ACGTCGGCCGTACACGGACCACAGTGCGGTCTCCGACACCGACGACACCCGGGAGACC

3181 AATTGTGCTCCCTCCACAAAGTTTACCCCAAAGGTTCTTCTAAGCCTTTATTGTCCCCT
-----+-----+-----+-----+-----+-----+ 3240
TTAACACGAGGGAGGTGTTTCAAATGGGGTTTTCCAAGAAGATTTCGAAATAACAGGGGA

3241 GGTAATGTTTCCCTGGCTGGGCGCGGTGGCTCCACGCCTGTAATCCCAGCACTTTGGGA
-----+-----+-----+-----+-----+-----+ 3300
CCATTTACAAAGGGACCGACCCGCGCCACCGAGGTGCGGACATTAGGGTCTGTAAACCCT

16/22

3301 GGCCGAGGCGGGTGGATCCACCTAAGGTCAGGAGTTTGAGATCCAGCCTGCCCAACATGG
-----+-----+-----+-----+-----+ 3360
CCGGCTCCGCCCACCTAGGTGGATTCCAGTCCTCAAACCTAGGTCGGACGGGTTGTACC

3361 TGAAACCTYGTCTTCTACTAAAAATACACAACCTTAGCCAGTCTTGTTGGCGMACGCCTGTA
-----+-----+-----+-----+-----+ 3420
ACTTTGGARCAAAGATGATTTTTATGTGTTGAATCGGTGAGAACAACCGCKTGCGGACAT

3421 ATSTTCAGYTAGGGACGCTGAGGCAGGAGAATCGTTTGAACCCAAGAAAGAGGTGGA
-----+-----+-----+-----+-----+ 3480
TASAAGTCRATGATCCCTGCGACTCCGTCTCTTAGCAAACCTTGGGTTCTTTCTCCACCT

3481 GGTGTVGGTGAGCCAAGATTGCGCCAHTGCACTCCAGCCTGGGCAACAGAGGGAGAYTCC
-----+-----+-----+-----+-----+ 3540
CCAACBCCACTCGGTTCTAACGCGGTDACGTGAGGTGCGACCCGTTGTCTCCCTCTRAGG

3541 ATCGCCCCCCCCAACAAAAAAGTTTCCCATACAYTGGCSTGCCCCAAAACCCACT
-----+-----+-----+-----+-----+ 3600
TAGCGGGGGGGGTTGTTTTTTTTTTCAAAGGGTATGTRACCGSACGGGGTTTTGGGTGA

3601 AACAAATTTAGCAAAACAGTCCAGGCCAAAGAGGAAGCATTTYATGTTCAATAAGAAACC
-----+-----+-----+-----+-----+ 3660
TTGTTAAAATCGTTTTGTGTCAGGTCCGGTTCTCCTTCGTAAARTACAAGTTATTCTTTGG

3661 CAGCCATTCCGCATGGCTGGTTCCTGAGTGGCTYTGGTGATACTCTCCAGCCACCTGCTG
-----+-----+-----+-----+-----+ 3720
GTCGGTAAGGCGTACCGACCAAGGACTCACCGARACCACTATGAGAGGTCGGTGGACGAC

3721 ACATTGAGAATTTAGACYTCGGGACTGCTGTTGCGGTACCGTGTGTGTGACACCTGCCA
-----+-----+-----+-----+-----+ 3780
TGTAACCTCTTAAAGTCTGRAGCCCTGACGACAACGCCATGGCACACARACTGTGGACGGT

3781 GCAGCCCTTTGCTATTTGCGCGCAGGATGGGGGTGACTGCCCAGACATTCCCGCTAGATA
-----+-----+-----+-----+-----+ 3840
CGTCGGGAAACGATAAACGCGCGTCTTACCCCACTGACGGGTCTGTAAGGGCGATCTAT

3841 GGTTTTGATTTCGGGGCAGCCTTTCAGATGCGGCAGACATACAACACCTGTACTTTAGA
-----+-----+-----+-----+-----+ 3900
CCAAAACATAAGGCCCGTCGGAAAGTCTACGCCGTCTGTATGTTGTGGACATGAAATCT

3901 GTTTTAAGGGAAAAAATCAGAAGTGCTGGTTAGATAGTAAAACTTAGGATAACTTA
-----+-----+-----+-----+-----+ 3960
CAAAATTCCTTTTTTTTTTAGTCTTCACGACCAATCTATCATTTTTGAATCCTATTGAAT

3961 GAAAGGCTAGTTTTAGCTTCCTTTGTGGCTCCCCTGGTGCAAAACAATTAGCAGTTATGC
-----+-----+-----+-----+-----+ 4020
CTTTCCGATCAAAATCGAAGGAAACACCGAGGGGACCACGTTTTGTTAATCGTCAATACG

4021 AATGGACCTGATTCTAGTTTATTCTAATTAAGAAGTGAGGCCGGGTTTGRACCTCGTTCC
-----+-----+-----+-----+-----+ 4080
TTACCTGGACTAAGATCAAATAAGATTAATTCTTCACTCCGGCCCAAACYTGAAGCAAGG

4081 TGAATACAATCTTGAGTAACTGGGAAAGTCTGAGTGAAAGGATGGCCTCATTCTCTTTCT
-----+-----+-----+-----+-----+ 4140
ACTTATGTTAGAACTCATTGACCCTTTCAGACTCACTTTCCTACCGGAGTAAGAGAAAGA

SUBSTITUTE SHEET (RULE 26)

Figure 7 cont'd

17/22

```
4141  AATCTTGCTGGTTTCAAGATTAGAAAAATGGCATTATTTGATCTGAAATGTTTGAGAARAC
      -----+-----+-----+-----+-----+-----+
      TTAGAACGACCAAAGTTCTAATCTTTTACCGTAATAAACTAGACTTTACAAACTCTTYTG
                                         4200

4201  ACGAATAAAGTTACTTGGGCAGAAAAAAAAA
      -----+-----+-----+-----+-----+
      TGCTTATTTCAATGAACCCGTCTTTTTTTTTT
                                         4231
```

18/22

Figure 8. Coding region of human PSKC cDNA.

```

71  ATGGAAGCCTTACGCTTTTACAGTTCACTGTGTAAAGAGAGCACGACGGCACCCTGG
-----+-----+-----+-----+-----+-----+-----+
130  TACCTTTTCGGAATGCGAAAATGTCAAGTGACACATTTCTCTCGTGCTGCCGTGGCGACC

131  AAGTGGGCGCAGGTGACTTTCTGGTGTCCAGAGGAGCAGCTGTGTCACTTGTGGCTGCAG
-----+-----+-----+-----+-----+-----+
190  TTCACCCGCGTCCACTGAAAGACCACAGGTCTCCTCGTCGACACAGTGAACACCGACGTC

191  ACCCTGCGGGAGATGCTGGAGAAGCTGACGTCCAGACCAAAGCATTACTGGTATTTATC
-----+-----+-----+-----+-----+-----+
250  TGGGACGCCCTCTACGACCTCTTCGACTGCAGGTCTGGTTTCGTAAATGACCATAAATAG

251  AACCCGTTTGGAGGAAAAGGACAAGGCAAGCGGATATATGAAAGAAAAGTGGCACCCTG
-----+-----+-----+-----+-----+-----+
310  TTGGGCAAACCTCCTTTTCCTGTTCCGTTCCGCTATATACTTTCTTTTCACCGTGGTGAC

311  TTCACCTTAGCCTCCATCACCCTGACATCATCGTTACTGAACATGCTAATCAGGCCAAG
-----+-----+-----+-----+-----+-----+
370  AAGTGGAATCGGAGGTAGTGGTGAAGTAGTAGCAATGACTTGTACGATTAGTCCGGTTC

371  GAGACTCTGTATGAGATTAAACATAGACAAATACGACGGCATCGTCTGTGTGGCGGAGAT
-----+-----+-----+-----+-----+-----+
430  CTCTGAGACATACTCTAATTGTATCTGTTTATGCTGCCGTAGCAGACACAGCCGCTCTA

431  GGTATGTTTCAGCGAGGTGCTGCACGGTCTGATTGGGAGGACGCAGAGGAGCGCCGGGTC
-----+-----+-----+-----+-----+-----+
490  CCATACAAGTCGCTCCACGACGTGCCAGACTAACCCTCCTGCGTCTCCTCGCGGCCCCAG

491  GACCAGAACCACCCCGGGCTGTGCTGGTCCCCAGTAGCCTCCGGATTGGAATCATTCCC
-----+-----+-----+-----+-----+-----+
550  CTGGTCTTGGTGGGGGCGGACACGACAGGGGTCATCGGAGGCCTAACCTTAGTAAGGG

551  GCAGGGTCAACGGAAGTGCCTGTGTTACTCCACCGTGGGCACCAGCGACGAGAAACCTCG
-----+-----+-----+-----+-----+-----+
610  CGTCCCAGTTGCCTGACGCACACAATGAGGTGGCACCCGTTGCTGCGTCTTTGGAGC

611  GCGCTGCATATCGTTGTTGGGGACTCGCTGGCCATGGATGTGTCCTCAGTCCACCACAAC
-----+-----+-----+-----+-----+-----+
670  CGCGACGTATAGCAACAACCCCTGAGCGACCGGTACCTACACAGGAGTCAGGTGGTGTG

671  AGCACACTCCTTCGCTACTCCGTGTCCCTGCTGGGCTACGGCTTCTACGGGGACATCATC
-----+-----+-----+-----+-----+-----+
730  TCGTGTGAGGAAGCGATGAGGCACAGGGACGACCCGATGCCGAAGATGCCCTGTAGTAG

731  AAGGACAGTGAGAAGAAACGGTGGTTGGGTCTTGCCAGATACGACTTTTCAGGTTTAAAG
-----+-----+-----+-----+-----+-----+
790  TTCCTGTCACTCTTCTTTGCCACCAACCCAGAACGGTCTATGCTGAAAAGTCCAAATTC

791  ACCTTCCTCTCCCACTGCTATGAAGGGACAGTGTCTTCCCTCCCTGCACAACACACG
-----+-----+-----+-----+-----+-----+
850  TGGAAGGAGAGGGTGGTGACGATACTTCCCTGTACAGGAAGGAGGGACGTGTTGTGTGC

```

Figure 8 cont'd

19/22

851 GTGGGATCTCCAAGGGATAGGAAGCCCTGCCGGGCAGGATGCTTTGTTTGCAGGCAAAGC
-----+-----+-----+-----+-----+-----+-----+ 910
CACCCCTAGAGGTTCCCTATCCTTCGGGACGGCCCGTCCTACGAAACAAACGTCCGTTTCG

911 AAGCAGCAGCTGGAGGAGGAGCAGAAGAAAGCACTGTATGGTTTGGAAAGCTGCGGAGGAC
-----+-----+-----+-----+-----+-----+-----+ 970
TTCGTGCGTCGACCTCCTCCTCGTCTTCTTTTCGTGACATACCAAACCTTCGACGCCTCCTG

971 GTGGAGGAGTGGCAAGTCGTCTGTGGGAAGTTTCTGGCCATCAATGCCACAAACATGTCC
-----+-----+-----+-----+-----+-----+-----+ 1030
CACCTCCTCACCGTTCAGCAGACACCCTTCAAAGACCGGTAGTTACGGTGTTTGTACAGG

1031 TGTGCTTGTCGCGCGGAGCCCCAGGGGCCTCTCCCCGGCTGCCCACTTGGGAGACGGGTCT
-----+-----+-----+-----+-----+-----+-----+ 1090
ACACGAACAGCGGCCTCGGGGTCCCCGGAGAGGGGCCGACGGGTGAACCCTCTGCCCAGA

1091 TCTGACCTCATCCTCATCCGGAATGCTCCAGGTTCAATTTTCTGAGATTTCTCATCAGG
-----+-----+-----+-----+-----+-----+-----+ 1150
AGACTGGAGTAGGAGTAGGCCTTTACGAGGTCCAAGTTAAAAGACTCTAAAGAGTAGTCC

1151 CACACCAACCAGCAGGACCAGTTTGACTTCACTTTTGTGTAAGTTTATCGCGTCAAGAAA
-----+-----+-----+-----+-----+-----+-----+ 1210
GTGTGGTTGGTCGTCTGTTCAAACCTGAAGTGAAAACAACCTTCAAATAGCGCAGTTCTTT

1211 TTCCAGTTTACGTGGAAGCACATGGAGGATGAGGACAGCGACCTCAAGGAGGGGGGGAAG
-----+-----+-----+-----+-----+-----+-----+ 1270
AAGGTCAAATGCAGCTTCGTGTACCTCCTACTCCTGTCGCTGGAGTTCTCCCCCCTTC

1271 AAGCGCTTTGGGCACATTTGCAGCAGCCACCCCTCCTGCTGCTGCACCGTCTCCAACAGC
-----+-----+-----+-----+-----+-----+-----+ 1330
TTCGCGAAACCCGTGTAAACGTGTCGCTGGTGGGAGGACGACGACGTGGCAGAGGTTGTCTG

1331 TCCTGGAAGTGCAGCGGGGAGGTCTGTCAGCCCTGCCATCGAGGTCAGAGTCCACTGC
-----+-----+-----+-----+-----+-----+-----+ 1390
AGGACCTTGACGCTGCCCCCTCCAGGACGTGTCGGGACGGTAGCTCCAGTCTCAGGTGACG

1391 CAGCTGGTTTCGACTCTTTGCACGAGAATTGGAAGAGAATCCGAAGCCAGACTCACACAGC
-----+-----+-----+-----+-----+-----+-----+ 1450
GTCGACCAAGCTGAGAAACGTGCTCTTAACCTTCTCTTAGGCTTCGGTCTGAGTGTGTCG

1451 TGA
--- 1453
ACT

20/22

Figure 9. Predicted amino acid sequence of human PSKC protein.

MEKPYAFTVHCVKRRRRHRWKWAQVTFWCPEEQQLCHLWLQTLREMLEKLTSRPKHLLVFI
1 -----+-----+-----+-----+-----+-----+-----+ 60

NPFGGKGQGKRIYERKVAPLFTLASITTDIIVTEHANQAKETLYEINIDKYDGIVCVGGD
61 -----+-----+-----+-----+-----+-----+-----+ 120

GMFSEVLHGLIGRTQRSAGVDQNHPRAVLVPSSLRIGIIPAGSTDCVCYSTVGTSDAETS
121 -----+-----+-----+-----+-----+-----+-----+ 180

ALHIVVGDSLAMDVSSVHHNSTLLRYSVSLLGYGFYGDIIKDSEKKRWLGLARYDFSGLK
181 -----+-----+-----+-----+-----+-----+-----+ 240

TFLSHHCYEGTVSFLPAQHTVGSPRDRKPCRAGCFVCRQSKQQLLEEEQKKALYGLEAAED
241 -----+-----+-----+-----+-----+-----+-----+ 300

VEEWQVVCGKFLAINATNMSCACRRSPRGLSPAHLGDGSSDLILIRKCSRFNFLRFLIR
301 -----+-----+-----+-----+-----+-----+-----+ 360

HTNQDQDFDFTFVEVYRVKKFQFTSKHMEDESDLKEGGKKRFGHICSSHPSCCCTVSNS
361 -----+-----+-----+-----+-----+-----+-----+ 420

SWNCDGEVLHSPAIEVRVHCQLVRLFARELEENPKPDSHS*
421 -----+-----+-----+-----+-----+-----+-----+ 461


21/22

PSKA_Human	-----MDPAGGPRGVLP--RP
PSKC_Human	MEKPYAFTVHCVKRARR----HRWKWAQVTFWCPEEQQLCHLWLQTLREMLEKLTSS--RP
PSKB_Human	MTVFFKTLRNNHKKTTAGLCLLTWGGHWLYGKHCDNLLRRAACQEAQVFGNQLIPPNAQV
	.
PSKA_Human	CRVLVLLNPRGGKKGKALQLFRSHVQPLLAEEAIEISFTLMLTERRNHARELVRSEELGRWDA
PSKC_Human	KHLLVFINPFGGKGQKRIYERKVAPLFTLASITTDIIVTEHANQAKETLYEINIDKYDG
PSKB_Human	KKATVFLNPAACKGKARTLFEKNAAPILHLSGMDVTIVKTDYEGQAKKLL--ELMENTDV
	. * .** **.
PSKA_Human	LVVMSGDGLMHEVVNGLMERPDWETAIQK--PLCILPAGSG--NALAASLNHYAGYEQVT
PSKC_Human	IVCVGGDGMFSEVLHGLIGRTQRSAGVDQNHPRAVLVPSSLRIGIIPAGSTDCVCYSTVG
PSKB_Human	IIVAGGDGTLQEVVTGVLRRTDEATFSKI--PIGFIPLGET-----SSLSHTLFAESGN
	.. *** **.
PSKA_Human	NEDLLTNCTLLLCRRLLSPMNLSSLHTASGLRFLFSVLSLAWGFADVDLESEKYRRLGEM
PSKC_Human	TSDAETSALHIVVGDSLAMDVSSVHHNSTLLRYSVSLLGYGFGYGDIIKDSEKKRWLGLA
PSKB_Human	KVQHITDATLAIVKGETVPLDFLQIKGEKEQPVFAMTGLRWGSFRDAGVKVSKYWYLGPL
	* * * * * *
PSKA_Human	RFTLTGTFRLAALR--TYRGRLAYLPVGR-VGSKTPASPVVVQ--QGPVDAHLVPLEEP
PSKC_Human	RYDFSGLKTFFLSHH--CYEGTVSFLPAQHTVGSPDRKPCRAG--CFVCRQSKQOLEEE
PSKB_Human	KIKAAHFFSTLKEWPQTHQASISYTGPTERPPNEPEETPVQRPSLYRRLRLASYWAQP
 *
PSKA_Human	VP-----SHWTVVPDEDFVLVLALLHSHLG--SEMFAAPMGRCAAGVMHLFYV
PSKC_Human	QKKALYGLEAAEDVEEWQVVCG-KFLAINATNMSCACRRSPRGLSPAHLGDGSSDLILI
PSKB_Human	QD-----ALSQEVSPVWKDVQLSTIELSITTR--NNQLDPTSKED--FLNICIE
 * . .
PSKA_Human	RAGVSRAMLLRLFLAMEKGRHMEYECPYLVYVPVVAFRLEPKDGKG-VFAVDGELMVRRA
PSKC_Human	RK-CSRFNPLRFLIRHTN-QQDQDFDTFVEYVRVKKFQFTSKHMEDESDLKEGGKKRFG
PSKB_Human	PDTISKGDFFITIGSRKVR--NPKLHVEGTECLQASQCTLLIPEGAGGSFSDIDSEYEAMP
	* . .
PSKA_Human	VQGQVHP-----NYFWMVSGCVEPPPSWKP-----QQMPPPPEEPL
PSKC_Human	HICSSHPSCCCTVSNSSWNCDGEVLHSPAIEVRVHCQLVRLFARELEENPKPDSSHS
PSKB_Human	VEVKLLPR-----KLQFFCD-----PRKRE-----QMLTSPTQ--
	* *

Figure 11

22/22

Phosphorylation of Sphingosine by Cloned Human SK_A



SEQUENCE LISTING

<110> NPS Allelix Corp.

<120> HUMAN SPHINOSINE KINASE HOMOLOGUES

<130> p128pct3

<140> not yet issued

<141> 2000-03-02

<150> U.S. 60/122,516

<151> 1999-03-02

<160> 17

<170> PatentIn Ver. 2.0

<210> 1

<211> 1447

<212> DNA

<213> Homo sapiens

<400> 1

```
gaggttatgg atccagcggg cggcccccgg ggcggtgctcc cgcggccctg ccgcgtgctg 60
gtgctgctga acccgcgcgg cggcaagggc aaggccttgc agctcttccg gagtcaagtg 120
cagccccctt tggctgaggc tgaaatctcc ttcacgctga tgctcactga gcggcggaac 180
cacgcgcggg agctgggtgc gtcggaggag ctgggcccgt gggacgctct ggtgggtcatg 240
tctggagacg ggctgatgca cgagggtgtg aacgggctca tggagcggcc tgactgggag 300
accgccatcc agaaaccctt gtgtatcctc ccagcaggct ctggcaacgc gctggcagct 360
tccttgaacc attatgctgg ctatgagcag gtcaccaatg aagacctcct gaccaactgc 420
acgctattgc tgtgccgcgc gctgctgtca ccatgaacc tgctgtctct gcacacggct 480
tcggggctgc gcctcttctc tgtgctcagc ctggcctggg gcttcattgc tgatgtggac 540
ctagagagtg agaagtatcg gcgtctgggg gagatgcgct tcaactctggg caccttctctg 600
cgtctggcag ccctgcgcac ctaccgcggc cgactggcct acctccctgt aggaagagtg 660
ggttccaaga cacctgcctc ccccggtgtg gtccagcagg gcccggtaga tgcacacctt 720
gtgccactgg aggagccagt gccctctcac tggacagtgg tgcccgcaga ggactttgtg 780
ctagtccctg cactgctgca ctgcacctg ggcagtgaga tgtttgctgc acccatgggc 840
cgctgtgcag ctggcgctcat gcatctgttc tacgtgcggg cgggagtgtc tcgtgccatg 900
ctgctgcgcc tcttccctggc catggagaag ggcaggcata tggagtatga atgccccctac 960
ttgggtatat tgcccgtggg cgctctccgc ttggagccca aggatgggaa aggtgtgttt 1020
gcagtggatg gggaattgat ggttaggcga gccgtgcagg gccagggtga cccaaactac 1080
ttctggatgg tcagcgggtg cgtggagccc ccgcccagct ggaagcccca gcagatgcc 1140
ccgccagaag agcccttatg acccctgggc cgcgctgtgc cttagtgtct acttgcagga 1200
cccttccctc ttccctaggg ctgcagggcc tgtccacagc tcctgtgggg gtggaggaga 1260
ctcctctgga gaagggtgag aagggtggag ctatgctttg gggggacagg ccagaatgaa 1320
gtcctgggtc aggagcccag ctggctgggc ccagctgcct atgtaaggcc ttctagtttg 1380
ttctgagacc cccacccccc gaaccaaata caaataaagt gacattccca aaaaaaaaaa 1440
aaaaaaaaa 1447
```

<210> 2

<211> 1155

<212> DNA

<213> Homo sapiens

<400> 2

```
atggatccag cgggcggccc cggggcgctg ctcccgcggc cctgcgcgct gctgggtgctg 60
ctgaaccgcg gcggcgggcaa gggcaaggcc ttgcagctct tccggagtca cgtgcagccc 120
cttttggctg aggttgaaat ctcccttcacg ctgatgtctc ctgagcggcg gaaccacgcg 180
cgggagctgg tgcggtcgga ggagctgggc cgctgggacg ctctgggtgg catgtctgga 240
gacgggctga tgcacgaggt ggtgaacggg ctcatggagc ggctgactg ggagaccgcc 300
```

```

atccagaaac ccctgtgtat cctcccagca ggctctggca acgcgctggc agcttccttg 360
aaccattatg ctggctatga gcaggtcacc aatgaagacc tcctgaccaa ctgcacgcta 420
ttgtctgtgcc gccggctgct gtcacccatg aacctgctgt ctctgcacac ggcttcgggg 480
ctgcgcctct tctctgtgct cagcctggcc tggggcttca ttgctgatgt ggacctagag 540
agtgagaagt atcggcgtct gggggagatg cgcttcaactc tgggcacctt cctgcgtctg 600
gcagccctgc gcacctaccg cggccgactg gcctacctcc ctgtaggaag agtgggttcc 660
aagacacctg cctccccctg tgtggtccag cagggcccgg tagatgcaca ccttgtgcca 720
ctggaggagc cagtgccttc tactggaca gtggtgcccg acgaggactt tgtgctagtc 780
ctggcactgc tgcactcgca cctgggcagt gagatgtttg ctgcacccat gggccgctgt 840
gcagctggcg tcatgcatct gttctactg cgggcgggag tgtctcgtgc catgctgctg 900
cgctcttccc tggccatgga gaagggcagg catatggagt atgaatgccc ctacttggtg 960
tatgtgcccc tggctgcctt ccgcttggag cccaaggatg ggaaagggtg gtttgacagt 1020
gatggggaat tgatggttag gcgagccgtg cagggccagg tgcacccaaa ctacttctgg 1080
atggtcagcg gttgcgtgga gccccgccc agctggaagc cccagcagat gccaccgcca 1140
gaagagccct tatga 1155

```

<210> 3

<211> 384

<212> PRT

<213> Homo sapiens

<400> 3

```

Met Asp Pro Ala Gly Gly Pro Arg Gly Val Leu Pro Arg Pro Cys Arg
  1              5              10              15

Val Leu Val Leu Leu Asn Pro Arg Gly Gly Lys Gly Lys Ala Leu Gln
  20              25              30

Leu Phe Arg Ser His Val Gln Pro Leu Leu Ala Glu Ala Glu Ile Ser
  35              40              45

Phe Thr Leu Met Leu Thr Glu Arg Arg Asn His Ala Arg Glu Leu Val
  50              55              60

Arg Ser Glu Glu Leu Gly Arg Trp Asp Ala Leu Val Val Met Ser Gly
  65              70              75              80

Asp Gly Leu Met His Glu Val Val Asn Gly Leu Met Glu Arg Pro Asp
  85              90              95

Trp Glu Thr Ala Ile Gln Lys Pro Leu Cys Ile Leu Pro Ala Gly Ser
 100              105              110

Gly Asn Ala Leu Ala Ala Ser Leu Asn His Tyr Ala Gly Tyr Glu Gln
 115              120              125

Val Thr Asn Glu Asp Leu Leu Thr Asn Cys Thr Leu Leu Leu Cys Arg
 130              135              140

Arg Leu Leu Ser Pro Met Asn Leu Leu Ser Leu His Thr Ala Ser Gly
 145              150              155              160

Leu Arg Leu Phe Ser Val Leu Ser Leu Ala Trp Gly Phe Ile Ala Asp
 165              170              175

Val Asp Leu Glu Ser Glu Lys Tyr Arg Arg Leu Gly Glu Met Arg Phe
 180              185              190

Thr Leu Gly Thr Phe Leu Arg Leu Ala Ala Leu Arg Thr Tyr Arg Gly
 195              200              205

```

Arg Leu Ala Tyr Leu Pro Val Gly Arg Val Gly Ser Lys Thr Pro Ala
 210 215 220
 Ser Pro Val Val Val Gln Gln Gly Pro Val Asp Ala His Leu Val Pro
 225 230 235 240
 Leu Glu Glu Pro Val Pro Ser His Trp Thr Val Val Pro Asp Glu Asp
 245 250 255
 Phe Val Leu Val Leu Ala Leu Leu His Ser His Leu Gly Ser Glu Met
 260 265 270
 Phe Ala Ala Pro Met Gly Arg Cys Ala Ala Gly Val Met His Leu Phe
 275 280 285
 Tyr Val Arg Ala Gly Val Ser Arg Ala Met Leu Leu Arg Leu Phe Leu
 290 295 300
 Ala Met Glu Lys Gly Arg His Met Glu Tyr Glu Cys Pro Tyr Leu Val
 305 310 315 320
 Tyr Val Pro Val Val Ala Phe Arg Leu Glu Pro Lys Asp Gly Lys Gly
 325 330 335
 Val Phe Ala Val Asp Gly Glu Leu Met Val Arg Arg Ala Val Gln Gly
 340 345 350
 Gln Val His Pro Asn Tyr Phe Trp Met Val Ser Gly Cys Val Glu Pro
 355 360 365
 Pro Pro Ser Trp Lys Pro Gln Gln Met Pro Pro Pro Glu Glu Pro Leu
 370 375 380

<210> 4

<211> 2306

<212> DNA

<213> Homo sapiens

<400> 4

agccgcgagc tggaccagcc gtgcaaactc ctagaagatg acggtgttct ttaaaacgct 60
 tcgaaatcac tggagaagaaa ctacagctgg gctctgcctg ctgacctggg gaggccattg 120
 gctctatgga aaacactgtg ataacctcct aaggagagca gcctgtcaag aagctcaggt 180
 gtttggaat caactcattc ctccaatgc acaagtgaag aaggccactg tttttctcaa 240
 tcctgcagct tgcaaaggaa aagccaggac tctatttgaa aaaaatgctg ccccgatttt 300
 acatttatct ggcatggatg tgactattgt taagacagat tatgaggagc aagccaagaa 360
 actcctggaa ctgatggaaa acacggatgt gatcattgtt gcaggaggag atgggacact 420
 gcaggagggt gttactgggt ttcttcgacg aacagatgag gctaccttca gtaagattcc 480
 cattggattt atcccactgg gagagaccag tagtttgagt catacctctt ttgccgaaag 540
 tggaaacaaa gtccaacata ttactgatgc cacacttgcc attgtgaaag gagagacagt 600
 tccacttgat ttcttgacga tcaagggtga aaaggaacag cctgtatttg caatgaccgg 660
 ccttcgatgg ggatctttca gagatgctgg cgtcaaagtt agcaagtact ggtatcttgg 720
 gcctctaaaa atcaaagcag cccacttttt cagcactctt aaggagtggc ctcagactca 780
 tcaagcctct atctcatata cgggacctac agagagacct cccaatgaac cagaggagac 840
 ccctgtacaa aggccttctt tgtacaggag aatattacga aggcttgcgt cctactgggc 900
 acaaccacag gatgcccttt cccaagaggt gagcccgag gtctggaaag atgtgcagct 960

```

gtccaccatt gaactgtcca tcacaacacg gaataatcag cttgaccoga caagcaaaga 1020
agatttttctg aatatctgca ttgaacctga caccatcagc aaaggagact ttataactat 1080
aggaagtcga aaggtgagaa accccaagct gcacgtggag ggcacggagt gtctccaagc 1140
cagccagtgc actttgctta tcccggaggg agcagggggc tcttttagca ttgacagtga 1200
ggagtatgaa gcgatgcctg tggaggtgaa actgctcccc aggaagctgc agttcttctg 1260
tgatcctagg aagagagaac agatgctcac aagccccacc cagtgagcag cagaagacaa 1320
gcactctgag accacacttt aggccaccgg tgggaccaa agggaacagg tgcctcagcc 1380
atcccaacag tgcgtcaga ggggtccccag ggcattttca tggcaagtac cctctgccc 1440
ccactccagc agtgcttccc aaagtgtgct ctgtcacctg ctttgcaatc ggcttccatt 1500
agcgcattgt ttattttggg gtgacgggtg gccctcctaa acacggactt tcctcaggct 1560
ggttcaagac ggaaaaggac tttcttctgt tttcttccaa agtgcaacca cagtggagag 1620
ccacgggtgg gcttagcctg cctaggccct tccatttctc ttctttgacc gtgctaggaa 1680
ttccaggaaa gtgcattcct gccctgggtg ccttttctta tgtctaggct cctccacagg 1740
tgctgctatt ttgtgagctc cggctcctgt ttagctttta tttcagttct aacctcagtc 1800
cagaaacata tgtgaggttg tttccctctt cagccacggc tacaataccg gaaaatgcta 1860
gtttttatatt atttttttaa gtagtgcttc cttaaagggt tgcattgagag ccacctgggg 1920
tacatgttga aaacttattt ggggtctacc ccaaacctaa taaccctaat ttggggatgg 1980
ggcccaggaa tatgcatttt taaaaagtca tctgcccttc ccaggtgatt ctgtaagttg 2040
tccttcaact gtacttggag aaatcgtgtt ttaaagcagt agtccacaaa gtattctgct 2100
cattgtcccc caaaagtatt ttgaaaaata atgtataccc tcacctatct aagttgatat 2160
ctaaaatttt atctaagtgt gtatctaaaa ttttctatgg gaagttaaat agttgacaaa 2220
gtatgtattt gctggtgtcg tgtaaatatt ggtattttta aataaaaact gttacatcac 2280
taawwwaaaa aaaaaaaaaa aaaaaa

```

<210> 5

<211> 1269

<212> DNA

<213> Homo sapiens

<400> 5

```

atgacgggtgt tcttttaaac gcttcgaaat cactggaaga aaactacagc tgggctctgc 60
ctgctgacct ggggaggcca ttggctctat ggaaaacact gtgataacct cctaaggaga 120
gcagcctgtc aagaagctca ggtgtttggc aatcaactca ttctcccaa tgcacaagtg 180
aagaaggcca ctgtttttct caatcctgca gcttgcaaag gaaaagccag gactctattt 240
gaaaaaatg ctgccccgat tttacattta tctggcatgg atgtgactat tgttaagaca 300
gattatgagg gacaagccaa gaaactcctg gaactgatgg aaaacacgga tgtgatcatt 360
gttgaggagg gagatgggac actgcaggag gttgttactg gtgttcttcg acgaacagat 420
gaggctacct tcagtaagat tcccatggga tttatccac tgggagagac cagtgtttg 480
agtcataccc tctttgccga aagtggaaac aaagtccaac atattactga tgccacactt 540
gccattgtga aaggagagac agttccactt gatttcttgc agatcaaggg tgaaaaggaa 600
cagcctgtat ttgcaatgac cggccttcga tggggatctt tcagagatgc tggcgtcaaa 660
gttagcaagt actggtatct tgggcctcta aaaatcaaag cagcccaact tttcagcact 720
cttaaggagt ggcctcagac tcatcaagcc tctatctcat acacgggacc tacagagaga 780
cctcccaatg aaccagagga gaccctgta caaaggcctt ctttgtacag gagaatatta 840
cgaaggcttg cgtoctactg ggcacaacca caggatgccc tttcccaaga ggtgagcccc 900
gaggtctgga aagatgtgca gctgtccacc attgaaactgt ccatcacaac acggaataat 960
cagcttgacc cgacaagcaa agaagatttt ctgaatatct gcattgaacc tgacaccatc 1020
agcaaaggag actttataac tataggaagt cgaaagggtg gaaaccccaa gctgcacgtg 1080
gagggcacgg agtgtctcca agccagccag tgcactttgc ttatcccggg gggagcaggg 1140
ggctctttta gcattgacag tgaggagtat gaagcgatgc ctgtggagggt gaaactgctc 1200
cccaggaagc tgcagttctt ctgtgatcct aggaagagag aacagatgct cacaagcccc 1260
accagtgga

```

<210> 6

<211> 422

<212> PRT

<213> Homo sapiens

<400> 6

Met Thr Val Phe Phe Lys Thr Leu Arg Asn His Trp Lys Lys Thr Thr

1	5	10	15
Ala Gly Leu Cys Leu Leu Thr Trp Gly Gly His Trp Leu Tyr Gly Lys	20	25	30
His Cys Asp Asn Leu Leu Arg Arg Ala Ala Cys Gln Glu Ala Gln Val	35	40	45
Phe Gly Asn Gln Leu Ile Pro Pro Asn Ala Gln Val Lys Lys Ala Thr	50	55	60
Val Phe Leu Asn Pro Ala Ala Cys Lys Gly Lys Ala Arg Thr Leu Phe	65	70	75
Glu Lys Asn Ala Ala Pro Ile Leu His Leu Ser Gly Met Asp Val Thr	85	90	95
Ile Val Lys Thr Asp Tyr Glu Gly Gln Ala Lys Lys Leu Leu Glu Leu	100	105	110
Met Glu Asn Thr Asp Val Ile Ile Val Ala Gly Gly Asp Gly Thr Leu	115	120	125
Gln Glu Val Val Thr Gly Val Leu Arg Arg Thr Asp Glu Ala Thr Phe	130	135	140
Ser Lys Ile Pro Ile Gly Phe Ile Pro Leu Gly Glu Thr Ser Ser Leu	145	150	155
Ser His Thr Leu Phe Ala Glu Ser Gly Asn Lys Val Gln His Ile Thr	165	170	175
Asp Ala Thr Leu Ala Ile Val Lys Gly Glu Thr Val Pro Leu Asp Phe	180	185	190
Leu Gln Ile Lys Gly Glu Lys Glu Gln Pro Val Phe Ala Met Thr Gly	195	200	205
Leu Arg Trp Gly Ser Phe Arg Asp Ala Gly Val Lys Val Ser Lys Tyr	210	215	220
Trp Tyr Leu Gly Pro Leu Lys Ile Lys Ala Ala His Phe Phe Ser Thr	225	230	235
Leu Lys Glu Trp Pro Gln Thr His Gln Ala Ser Ile Ser Tyr Thr Gly	245	250	255
Pro Thr Glu Arg Pro Pro Asn Glu Pro Glu Glu Thr Pro Val Gln Arg	260	265	270
Pro Ser Leu Tyr Arg Arg Ile Leu Arg Arg Leu Ala Ser Tyr Trp Ala	275	280	285
Gln Pro Gln Asp Ala Leu Ser Gln Glu Val Ser Pro Glu Val Trp Lys	290	295	300
Asp Val Gln Leu Ser Thr Ile Glu Leu Ser Ile Thr Thr Arg Asn Asn	305	310	315
Gln Leu Asp Pro Thr Ser Lys Glu Asp Phe Leu Asn Ile Cys Ile Glu			

325 330 335

Pro Asp Thr Ile Ser Lys Gly Asp Phe Ile Thr Ile Gly Ser Arg Lys
340 345 350

Val Arg Asn Pro Lys Leu His Val Glu Gly Thr Glu Cys Leu Gln Ala
355 360 365

Ser Gln Cys Thr Leu Leu Ile Pro Glu Gly Ala Gly Gly Ser Phe Ser
370 375 380

Ile Asp Ser Glu Glu Tyr Glu Ala Met Pro Val Glu Val Lys Leu Leu
385 390 395 400

Pro Arg Lys Leu Gln Phe Phe Cys Asp Pro Arg Lys Arg Glu Gln Met
405 410 415

Leu Thr Ser Pro Thr Gln
420

<210> 7

<211> 4231

<212> DNA

<213> Homo sapiens

<400> 7

atctgagatc atcgccgttg aggaaacaga cgttcacggg aaacatcaag gcagtggaaa 60
atggcagaaa atggaaaagc cttacgcttt tacagtccac tgtgtaaaga gagcacgacg 120
gcaccgctgg aagtgggcgc aggtgacttt ctgggtgtcca gaggagcagc tgtgtcactt 180
gtggctgcag accctgcggg agatgctgga gaagctgacg tccagaccaa agcatttact 240
ggtattttatc aaccctgttg gaggaaaagg acaaggcaag cggtatatatg aaagaaaagt 300
ggcaccactg ttcaccttag cctccatcac cactgacatc atcgttactg aacatgctaa 360
tcaggccaag gagactctgt atgagattaa catagacaaa tacgacggca tcgtctgtgt 420
cggcgagat ggtatgttca gcgaggtgct gcacgggtctg attgggagga cgcagaggag 480
cgccggggtc gaccagaacc acccccgggc tgtgtctggtc cccagtagcc tccggattgg 540
aatcattccc gcagggtcaa cggactgcgt gtgttactcc accgtgggca ccagcgacgc 600
agaaacctcg gcgctgcata tcgttggttg ggactcgctg gccatggatg gtcctcagt 660
ccaccacaac agcacactcc ttcgctactc cgtgtccctg ctgggctacg gcttctacgg 720
ggacatcatc aaggacagtg agaagaaacg gtgggtgggt cttgccagat acgacttttc 780
aggttttaag accttctct cccaccactg ctatgaaggg acagtgtcct tcctccctgc 840
acaacacacg gtgggatctc caagggatag gaagccctgc cgggcaggat gctttgtttg 900
caggcaaagc aagcagcagc tggaggagga gcagaagaaa gcaactgtatg gtttggaagc 960
tgcgaggagc gtggaggagt ggcaagtcgt ctgtgggaag tttctggcca tcaatgccac 1020
aaacatgtcc tgtgcttgtc gccggagccc caggggcctc tcccggctg cccacttggg 1080
agacgggtct tctgacctca tcctcatccg gaaatgctcc aggttcaatt ttctgagatt 1140
tctcatcagg cacaccaacc agcaggacca gtttgacttc acttttggtg aagtttatcg 1200
cgtcaagaaa ttccagttta cgtcgaagca catggaggat gaggacagcg acctcaagga 1260
gggggggaag aagcgctttg ggcacatttg cagcagccac ccctcctgct gctgcaccgt 1320
ctccaacagc tcctggaact gcgacgggga ggtcctgcac agccctgcca tcgaggtcag 1380
agtccactgc cagctgggtc gactctttgc acgagaattg gaagagaatc cgaagccaga 1440
ctcacacagc tgagaagccg gcgtcctgct ctcgaaactgg gaaagtgtga aaactattta 1500
agataattat tacagaccaa ttatgttgat atatacatat aaatgtagaa atttattttt 1560
gatagttaaa tcttgatttt agaagaaaac ccttttgta acaattttgt gtacatattt 1620
ggcattttca gttctgtacg catctgcggg ttgcagccca cgccgcttac tctcagcgga 1680
tgcaactgct cacttggggg cactggcctc ttaggtttta acgatgtcaa cagtgtagtt 1740
tagaaaatgg ccggttagtg gctctattgc aataatgtta gggacattat atgatttcca 1800
cgcaggtcac accatctggg cctgaggtag cagtgggtca ctttgatcca ctttgaggga 1860
cttattctgt aacggtttgt ggccaagttt tgggaagtgg ttgattctct ttgccttcac 1920
ttcaccttcc tcttcgttta cggtaggac atcgctgctt gatccttaca atactgtgca 1980

actgcaatgc	aacgtggccc	tgcttcaggt	gatccgcggg	aggggcctcc	acgccagcac	2040
cgggaaaggc	tgctggggcc	tccacacctg	cctcatcacg	ggggggaagc	tacgacaatc	2100
cggctgggaa	catgaccttg	gcgtctgttc	tgggaacaca	aatrataarc	tctggaarct	2160
ggcagtgtgt	aaagcactgg	caagtttggt	actgttaaaa	tgtcaaatac	caatgcttta	2220
tatcgacgcc	gaaatgctta	acacakccgg	gcttgggggc	agtcagggaag	aaaactggcc	2280
atccgtggag	gaggggccc	tcctggactc	ccgcaggayt	cctctgatgc	agggcctgaa	2340
gtctgtacac	gtggtccaaa	tttgtccttg	tcttttcttc	acactgagtt	ctctatatatt	2400
attgaacatc	ttgtcctttt	taarccamga	agtartgtta	actgcgtctc	ggatgtctgt	2460
cttttgtctc	sgaarccacr	awggatckct	ggtttcctct	ctgcagcgcg	agggctccgg	2520
cgaccagagg	atyctycccg	raaggsattc	ctgccgcgct	cccccgggca	cccctcaatt	2580
gtgtactacc	gtcccttggt	taakggtttg	tatccctgcc	cacstaagat	aatgtctgt	2640
aacggtagtt	ttgtttgaaa	atatgagaat	atgcggctta	aactttgatc	tgtaaggagc	2700
ggggcccgtg	cccgtttgga	gcacgctgta	gacmccgttc	ctcatgctgc	cgggtggggt	2760
ttgcagaagc	tcccttagtg	atttcatggt	taacaggcag	catcccattt	tcagaatttc	2820
ctggcattga	ttttatatatt	tgaagcatac	aggaaacttc	togtttccct	cgttttagccc	2880
ccaccagat	ccaggtgaaa	gggcagcttt	aatggtgggt	tttatggacc	accattatca	2940
gagagcactg	tgcaagccaa	atggtttcaa	taatgaatga	aaatttctgg	gtgtaaagag	3000
taaataatgcc	cctggctctt	ttctaccaat	gtttgcttcc	tggttgga	gaaaccaaag	3060
atttaagacg	ggctgcttct	tcccagactg	gctgtgccct	gcctgtggcc	cagcaacctg	3120
tgcagccggc	agtgtgcctg	gtgtcacgcc	aggaggtgt	ggctgctgtg	ggcctctgtg	3180
aattgtgctc	cctccacaaa	gtttacccca	aaaggttctt	ctaagccttt	attgtccct	3240
ggtaaatggt	tccttggtg	ggcgcggtg	ctccacgcct	gtaatcccag	cactttggga	3300
ggccgaggcg	ggtggatcca	cctaaggtca	ggagtttgag	atccagcctg	ccaacatgg	3360
tgaaacctyg	tttctactaa	aaatacacaa	cttagccagt	cttgttggcg	macgcctgta	3420
atsttcagyt	actagggacg	ctgaggcagg	agaatcgttt	gaacccaaga	aagaggtgga	3480
ggttgvvggtg	agccaagatt	gcgccahtgc	actccagcct	gggcaacaga	gggagaytcc	3540
atcgcccccc	cccaacaaaa	aaaaaagttt	cccatacayt	ggcstgcccc	aaaaccact	3600
aacaatttta	gcaaaacagt	ccaggccaaa	gaggaagcat	ttyatgttca	ataagaaacc	3660
cagccattcc	gcatggctgg	ttcctgagtg	gctytgggtga	tactctccag	ccacctgctg	3720
acattgagaa	tttcagacyt	cgggactgct	gttgcggtac	cgtgtgtytg	acacctgcca	3780
gcagcccttt	gctatttgcg	cgcaggatgg	gggtgactgc	ccagacattc	ccgctagata	3840
ggttttgatt	tccggggcag	cctttcagat	gcggcagaca	tacaacacct	gtactttaga	3900
gttttaaggg	aaaaaaaaat	cagaagtgtc	ggttagatag	taaaaactta	ggataactta	3960
gaaaggctag	ttttagcttc	ctttgtggct	cccctgggtgc	aaaacaatta	gcagttatgc	4020
aatggacctg	attctagttt	attctaatta	agaagtgagg	ccgggttgr	acttcgttcc	4080
tgaatacaat	cttgagtaac	tgggaaagtc	tgagtgaag	gatggcctca	ttctctttct	4140
aatcttgctg	gtttcaagat	tagaaaatgg	cattatttga	tctgaaatgt	ttgagaarac	4200
acgaataaag	ttacttgggc	agaaaaaaaa	a			4231

<210> 8

<211> 1383

<212> DNA

<213> Homo sapiens

<400> 8

atggaaaagc	cttacgcttt	tacagttcac	tgtgtaaaga	gagcacgacg	gcaccgctgg	60
aagtgggcgc	aggtgacttt	ctggtgtcca	gaggagcagc	tgtgtcactt	gtggctgcag	120
accctgcggg	agatgctgga	gaagctgacg	tccagaccaa	agcatttact	ggtatttacc	180
aacccgtttg	gaggaaaagg	acaaggcaag	cggatatatg	aaagaaaagt	ggcaccactg	240
ttcaccttag	cctccatcac	cactgacatc	atcgttactg	aacatgctaa	tcaggccaag	300
gagactctgt	atgagattaa	catagacaaa	tacgacggca	tcgtctgtgt	cggcggagat	360
ggtatgttca	gcgaggtgct	gcacgggtctg	attgggagga	cgcagaggag	cgcgggggtc	420
gaccagaacc	acccccgggc	tgtgctggtc	cccagtagcc	tccggattgg	aatcattccc	480
gcaggggtcaa	cggactgcgt	gtgttactcc	accgtgggca	ccagcgacgc	agaaacctcg	540
gcgctgcata	tcgttggttg	ggactcgctg	gccatggatg	tgtcctcagt	ccaccacaac	600
agcacactcc	ttcgctactc	cgtgtccctg	ctgggctacg	gcttctacgg	ggacatcatc	660
aaggacagtg	agaagaaacg	gtgggtgggt	cttgccagat	acgacttttc	aggtttaaag	720
accttcctct	cccaccactg	ctatgaagct	acagtgtcct	tctcctctgc	acaacacacg	780
gtgggatctc	caagggatag	gaagccctgc	cgggaggatg	gctttgtttg	caggcaaaag	840
aagcagcagc	tggaggagga	gcagaagaaa	gcactgtatg	gtttggaagc	tgccggaggac	900

```

gtggaggagt ggcaagtcgt ctgtgggaag tttctggcca tcaatgccac aaacatgtcc 960
tgtgtttgtc gccggagccc caggggcctc tccccggctg cccacttggg agacgggtct 1020
tctgacctca tcctcatccg gaaatgctcc aggttcaatt ttctgagatt tctcatcagg 1080
cacaccaacc agcaggacca gtttgacttc acttttgttg aagtttatcg cgtcaagaaa 1140
ttccagttta cgtcgaagca catggaggat gaggacagcg acctcaagga gggggggaag 1200
aagcgctttg ggcacatttg cagcagccac ccctcctgct gctgcaccgt ctccaacagc 1260
tcctggaact gcgacgggga ggtcctgcac agccctgcca tcgaggtcag agtccactgc 1320
cagctggttc gactctttgc acgagaattg gaagagaatc cgaagccaga ctcacacagc 1380
tga 1383

```

<210> 9

<211> 460

<212> PRT

<213> Homo sapiens

<400> 9

```

Met Glu Lys Pro Tyr Ala Phe Thr Val His Cys Val Lys Arg Ala Arg
 1          5          10          15

Arg His Arg Trp Lys Trp Ala Gln Val Thr Phe Trp Cys Pro Glu Glu
          20          25          30

Gln Leu Cys His Leu Trp Leu Gln Thr Leu Arg Glu Met Leu Glu Lys
          35          40          45

Leu Thr Ser Arg Pro Lys His Leu Leu Val Phe Ile Asn Pro Phe Gly
 50          55          60

Gly Lys Gly Gln Gly Lys Arg Ile Tyr Glu Arg Lys Val Ala Pro Leu
 65          70          75          80

Phe Thr Leu Ala Ser Ile Thr Thr Asp Ile Ile Val Thr Glu His Ala
          85          90          95

Asn Gln Ala Lys Glu Thr Leu Tyr Glu Ile Asn Ile Asp Lys Tyr Asp
          100          105          110

Gly Ile Val Cys Val Gly Gly Asp Gly Met Phe Ser Glu Val Leu His
          115          120          125

Gly Leu Ile Gly Arg Thr Gln Arg Ser Ala Gly Val Asp Gln Asn His
          130          135          140

Pro Arg Ala Val Leu Val Pro Ser Ser Leu Arg Ile Gly Ile Ile Pro
          145          150          155          160

Ala Gly Ser Thr Asp Cys Val Cys Tyr Ser Thr Val Gly Thr Ser Asp
          165          170          175

Ala Glu Thr Ser Ala Leu His Ile Val Val Gly Asp Ser Leu Ala Met
          180          185          190

Asp Val Ser Ser Val His His Asn Ser Thr Leu Leu Arg Tyr Ser Val
          195          200          205

Ser Leu Leu Gly Tyr Gly Phe Tyr Gly Asp Ile Ile Lys Asp Ser Glu
          210          215          220

Lys Lys Arg Trp Leu Gly Leu Ala Arg Tyr Asp Phe Ser Gly Leu Lys
          225          230          235          240

```


Thr Phe Leu Ser His His Cys Tyr Glu Gly Thr Val Ser Phe Leu Pro
 245 250 255
 Ala Gln His Thr Val Gly Ser Pro Arg Asp Arg Lys Pro Cys Arg Ala
 260 265 270
 Gly Cys Phe Val Cys Arg Gln Ser Lys Gln Gln Leu Glu Glu Glu Gln
 275 280 285
 Lys Lys Ala Leu Tyr Gly Leu Glu Ala Ala Glu Asp Val Glu Glu Trp
 290 295 300
 Gln Val Val Cys Gly Lys Phe Leu Ala Ile Asn Ala Thr Asn Met Ser
 305 310 315 320
 Cys Ala Cys Arg Arg Ser Pro Arg Gly Leu Ser Pro Ala Ala His Leu
 325 330 335
 Gly Asp Gly Ser Ser Asp Leu Ile Leu Ile Arg Lys Cys Ser Arg Phe
 340 345 350
 Asn Phe Leu Arg Phe Leu Ile Arg His Thr Asn Gln Gln Asp Gln Phe
 355 360 365
 Asp Phe Thr Phe Val Glu Val Tyr Arg Val Lys Lys Phe Gln Phe Thr
 370 375 380
 Ser Lys His Met Glu Asp Glu Asp Ser Asp Leu Lys Glu Gly Gly Lys
 385 390 395 400
 Lys Arg Phe Gly His Ile Cys Ser Ser His Pro Ser Cys Cys Cys Thr
 405 410 415
 Val Ser Asn Ser Ser Trp Asn Cys Asp Gly Glu Val Leu His Ser Pro
 420 425 430
 Ala Ile Glu Val Arg Val His Cys Gln Leu Val Arg Leu Phe Ala Arg
 435 440 445
 Glu Leu Glu Glu Asn Pro Lys Pro Asp Ser His Ser
 450 455 460

<210> 10

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 10

aaccgcgcgc gcgcaagggc aaggc

25

<210> 11

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 11

aagggaagg ccttcagct cttcc

25

<210> 12

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 12

caggcgcgc catgagcccg ttcac

25

<210> 13

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 13

gcatcagccc gtctccagac atga

24

<210> 14

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 14

tgcaaattctc tagaagatga cgggtg

25

<210> 15

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 15

tataactcaaa ctactggtct ctccaag

27

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 16

ttaacataga caaatacgac ggcatcg

27

<210> 17

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 17

acacatccat ggccagcgag tcc

23

THIS PAGE BLANK (USPTO)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 September 2000 (08.09.2000)

PCT

(10) International Publication Number
WO 00/52173 A3

- (51) International Patent Classification⁷: **C12N 15/54, 9/12, A61K 31/70**
- (21) International Application Number: **PCT/CA00/00223**
- (22) International Filing Date: **2 March 2000 (02.03.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/122,516 2 March 1999 (02.03.1999) US
- (71) Applicant (*for all designated States except US*): **NPS ALLELIX CORP. [CA/CA]; 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA).**
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **MUNROE, Donald [CA/CA]; 27 Wakefield Lane, Waterdown, Ontario L0R 2N3 (CA). GUPTA, Ashwani [CA/CA]; 7031 Dunrobin Way, Mississauga, Ontario L5N 6Y4 (CA). FALZONE, Germaine, R. [CA/CA]; 34 Brady Crescent, North York, Ontario M3L 2B5 (CA).**
- (74) Agents: **VAN ZANT, Joan, M. et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montreal, Quebec H3A 2Y3 (CA).**
- (81) Designated States (*national*): **AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**
- Published:
— *With international search report.*
- (88) Date of publication of the international search report:
15 February 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **CLONED HUMAN SPHINGOSINE KINASE HOMOLOGUES**

(57) Abstract: The present invention provides newly identified and isolated polynucleotides and their polypeptides and their uses and in particular to newly identified and isolated polynucleotides and polypeptides of the sphingosine kinase family. Three isolated polynucleotides and polypeptides for three human SK homologues are described: SKA, SKB and SKC.

WO 00/52173 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/00223

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/54 C12N9/12 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KOHAMA, T. ET AL.: "Molecular Cloning and Functional Characterization of Murine Sphingosine Kinase" J. BIOL. CHEM., vol. 273, no. 37, 11 September 1998 (1998-09-11), pages 23722-23728, XP002150781 figure 1	1,2,4,6, 8-12
A	BANNO, Y. ET AL.: "Evidence for the presence of multiple forms of Sph kinase in human platelets" BIOCHEM. J., vol. 335, 1998, pages 301-304, XP002150782 page 304, column 1, paragraph 2 -/-	1-14

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 October 2000

Date of mailing of the international search report

07/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mata Vicente, T.

INTERNATIONAL SEARCH REPORT

Int lional Application No

PCT/CA 00/00223

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>PITSON, S. M. ET AL.: "Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes"</p> <p>BIOCHEMICAL J., vol. 350, Part 2, 1 September 2000 (2000-09-01), pages 429-441, XP000946990 page 430, column 2, paragraph 5</p>	

THIS PAGE BLANK (USPTO)